1	Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status
2	among women and children in two districts in the Northern Region of Ghana: Protocol for
3	the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized
4	controlled trial.
5	
6	Reina Engle-Stone ^{1,2} *, K Ryan Wessells ^{1,2} , Marjorie J. Haskell ^{1,2} , Sika M. Kumordzie ² , Charles
7	D. Arnold ² , Jennie N. Davis ² , Emily R. Becher ² , Ahmed D. Fuseini ³ , Kania W. Nyaaba ³ , Xiuping
8	(Jenny) Tan ² , Katherine P. Adams ^{1,2} , Georg Lietz ⁴ , Stephen A. Vosti ^{2,5} , Seth Adu-Afarwuah ³
9	
10	
11	¹ Department of Nutrition, University of California, Davis, USA
12	² Institute for Global Nutrition, University of California, Davis, USA
13	³ Department of Food Science and Nutrition, University of Ghana, Legon, Ghana
14	⁴ Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University,
15	Newcastle upon Tyne, UK
16	⁵ Department of Agricultural and Resource Economics, University of California, Davis, USA
17	
18	
19	* Corresponding author
20	E-mail: renglestone@ucdavis.edu (RES)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21	Pubmed indexing: Engle-Stone, Wessells, Haskell, Kumordzie, Arnold, Davis, Becher, Fuseini,
22	Nyaaba, Tan, Adams, Lietz, Vosti, Adu-Afarwuah
23	Short title: Randomized controlled trial of multiple micronutrient-fortified bouillon in Ghana
24	Sources of support: This work was supported, in whole or in part, by a grant from Helen Keller
25	International (66504-UCD-01), through support from the Bill & Melinda Gates Foundation
26	(INV-007916), to the University of California, Davis. Under the grant conditions of the
27	Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to
28	the Author Accepted Manuscript version that might arise from this submission.
29	Competing interests: All authors declare no competing interests.
30	
31	Data availability: Consistent with policy of the Bill & Melinda Gates Foundation, data and forms
32	will be made available online at osf.io/t3zrn/ three years after the completion of data collection.
33	
34	Authors' Contributions: Conceptualization of the study design: RES, KRW, MJH, SMK, CDA,
35	KPA, SAV, SAA; methods development: all co-authors; manuscript drafting: RES, KRW, MJH,
36	CDA, JND, SAA; manuscript review and editing: all co-authors; supervision and project
37	administration: RES, KRW, MJH, SMK, JND, ERB, ADF, KWN, KPA, SAV, SAA. All authors
38	have read and agreed to the published version of the manuscript.
39	
40	List of Abbreviations
41	AGP, alpha-1-acid glycoprotein; BIS, Body iron stores; BMI, Body mass index; BP, Blood
42	pressure; CA/TSC, Citric acid/trisodium citrate; CoMIT, Condiment Micronutrient Innovation
43	Trial; CRP, C-reactive protein; CSIRO, Commonwealth Scientific and Industrial Research
44	Organization; DSMB, Data and safety monitoring board; DFE, Dietary folate equivalents; ERC,

Ethical review committee; EYT, Early Years Toolbox; FACT, Fortification Assessment 45 Coverage Tool; FDA, Food and Drugs Authority; FGD, Focus group discussion; FFO, Food 46 frequency questionnaire; FePP, Ferric pyrophosphate; GHS, Ghana Health Service; Hb, 47 Hemoglobin; HCG, Human chorionic gonadotropin; Hct, Hematocrit; HFIAS, Household Food 48 Insecurity Access Scale; HH, Household; HOME, Home Observation Measurement of the 49 Environment; HPLC, High performance liquid chromatography; HWISE, Household Water 50 51 Insecurity Experiences; ID, Identification; IRB, Institutional Review Board; KAP, Knowledge Attitudes and Practices; MDAT, Malawi Development Assessment Tool; MDD-W, Minimum 52 53 Dietary Diversity- Women; MUAC, Mid-upper arm circumference; OAA, Opinions, attitudes, and acceptance; PI, Personal identifying information; RAE, Retinol Activity Equivalents; RBC, 54 Red blood cell; RBP, Retinol binding protein 4; RDA, Recommended dietary allowance; RDT, 55 Rapid diagnostic test; RID, Retinol isotope dilution; RISE, Research Institutes of Sweden Ab; 56 57 SAE, Serious Adverse Event; SAP, Statistical analysis plan; SES, Socioeconomic status; SOP, Standard operating procedure; STEPS, WHO STEPwise Approach to NCD Risk Factor 58 Surveillance; sTfR, Soluble transferrin receptor; WRA, Women of Reproductive Age; UL, 59 Tolerable Upper Intake level; ZPP, Zinc protoporphyrin 60

61 ABSTRACT

62

62	
63	Introduction: Micronutrient deficiencies are prevalent in West Africa, particularly among
64	women of reproductive age (WRA) and young children. Bouillon is a promising food
65	fortification vehicle due to its widespread consumption. This study aims to evaluate the impact
66	of multiple micronutrient-fortified bouillon cubes, compared to control bouillon cubes (fortified
67	with iodine only), on micronutrient status and hemoglobin concentrations among lactating and
68	non-lactating WRA and young children in northern Ghana.
69	
70	Methods: This randomized, controlled doubly-masked trial will be conducted in the Kumbungu
71	and Tolon districts in the Northern Region of Ghana, where prior data indicate multiple
72	micronutrient deficiencies are common. Participants will be: 1) non-pregnant non-lactating WRA
73	(15-49 y), 2) children 2-5 y, and 3) non-pregnant lactating women 4-18 months postpartum.
74	Eligible participants will be randomly assigned to receive household rations of one of two types
75	of bouillon cubes: 1) a multiple micronutrient-fortified bouillon cube containing vitamin A, folic
76	acid, vitamin B12, iron, zinc, and iodine, or 2) a control cube containing iodine only.
77	
78	Each participant's household will receive a ration of bouillon cubes every 2 weeks, and
79	households will be advised to prepare meals as usual, using the study-provided cubes. The trial
80	duration will be 9 months for non-pregnant non-lactating WRA and children, and 3 months for
81	lactating women. The primary outcomes will be changes in biomarkers of micronutrient status
82	and hemoglobin. Secondary outcomes will include change in prevalence of micronutrient
83	deficiency and anemia; dietary intake of bouillon and micronutrients; inflammation, malaria, and
84	morbidity symptoms; and child growth and development.
85	

86	Discussion: Evidence from this study will inform discussions about bouillon fortification in
87	Ghana and West Africa.
88	
89	Trial Registration: The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-
90	African Clinical Trial Registry (PACTR202206868437931). This manuscript reflects protocol
91	version 4 (August 29, 2022).
92	
93	Keywords: Bouillon, fortification, micronutrients, deficiency, anemia, young children, women,
94	Ghana, West Africa
95	
96	
97	
98	
99	
100	
101	

102 Introduction

103

104	Micronutrient deficiencies are severe and widespread in West Africa, particularly among young
105	children, pregnant and lactating women, and women of reproductive age [1-3]. These
106	deficiencies have developmental and physical consequences, including increased risk of
107	morbidity and mortality [4], which, in turn, have economic consequences [5]. While various
108	programs to address micronutrient deficiencies have been scaled up, including industrial
109	fortification of cooking oil and wheat flour with micronutrients [6], it is unlikely that a single
110	such program will eliminate all micronutrient deficiencies, since delivery platforms may provide
111	only a subset of nutrients or reach only a subset of the deficient population.
112	
113	In Ghana, micronutrient deficiencies remain common, particularly among women and children,
114	despite the presence of various decades-long micronutrient intervention programs [7]. For
115	example, in the 2017 Ghana Micronutrient Survey, the percentage of preschool children who had
116	iron deficiency (serum ferritin <12 μ g/L adjusted for inflammation) was 40% for the Northern
117	Belt, 18% for the Middle Belt, and 13% for the Southern Belt [8]. Likewise, the percentage of
118	children with vitamin A deficiency (retinol binding protein <0.70 µmol/L, adjusted for
119	inflammation) was 31%, 18% and 17% for the Northern, Middle, and Southern Belts,
120	respectively. Among non-pregnant WRA (15-49 y), the prevalence of iron deficiency (serum
121	ferritin <15 μ g/L, adjusted for inflammation) followed the same pattern as that for pre-school
122	children, with the Northern Belt (22%) being worst off, compared with the Middle (11%) and
123	Southern (14%) Belts. Approximately half of women (50.8% in the Northern belt) had serum
124	folate concentrations < 10 nmol/L [8].
125	

Wheat flour fortification (iron, zinc, vitamin A, folic acid, and other B vitamins) and cooking oil 126 fortification (vitamin A) are mandatory in Ghana; however, achieving and sustaining high 127 compliance with target fortification levels is a challenge [9]. The 2017 Ghana Micronutrient 128 Survey found that only 56% of oil samples (36% in the Northern Belt) were adequately fortified 129 with vitamin A (≥ 10 mg/kg vitamin A), and only 6% of wheat flour samples (6% in the Northern 130 Belt) had adequate iron concentrations (\geq 58.5 mg/kg as mandated by Ghana's food fortification 131 132 standards) [10]. Similar challenges with implementation of fortification programs have been observed elsewhere in the region [11]. Further efforts are thus required to address the high 133 134 prevalence of micronutrient deficiencies in Ghana and elsewhere in West Africa. 135 Bouillon cubes are widely consumed in West Africa and therefore hold great potential for 136

addressing micronutrient deficiencies in the region [12-14]. Bouillon is particularly attractive as
a food vehicle because consumption is high even among subsets of the population typically at
risk for micronutrient deficiencies, such as those residing in rural areas and households with low
socioeconomic status [12, 15]. Estimates of the proportion of households consuming bouillon in
the past week have ranged from 79% to 99% in Burkina Faso, Cameroon, Niger, and Senegal
[16]. In Ghana, preliminary analyses of household data [17] suggested that 72% of households
had acquired bouillon products in the prior 18 days.

144

In West Africa, some brands of bouillon have been produced with iodized salt since the 1990s,
and bouillon products fortified with iron or vitamin A, in addition to iodine, have been
introduced by some companies on a voluntary basis [18]. A study in Senegal found that iodine
fortification of bouillon could potentially contribute substantially to iodine intake, by providing
between 7%-115% of the recommended daily intake, depending on the iodine content of the
cubes [19]. In northern Ghana, a study of schoolchildren 6-13 years of age [20] found that

around two-thirds (2/3) of dietary iodine was obtained from iodine-fortified bouillon cubes. 151 Other modelling studies have found that bouillon cube fortified with vitamin A could reduce the 152 prevalence of inadequate vitamin A intakes without leading to an increase in excessive intakes 153 among women or children in Cameroon [21], and would complement other intervention 154 programs in reducing inadequate intake of vitamin A [22]. 155 156 157 The foregoing evidence suggests that the fortification of bouillon, in combination with other ongoing measures, could contribute to the prevention of micronutrient deficiencies in Ghana. 158 159 However, the levels of micronutrients that are currently included in commercial bouillon products on a voluntary basis (e.g., iron) may not be sufficient to meet public health needs [23]. 160 Moreover, no commercial bouillon products have been released that address deficiencies in other 161 key nutrients, such as zinc, folate, and vitamin B-12. Therefore, research is needed to explore the 162 efficacy of fortified bouillon for addressing micronutrient deficiencies. To our knowledge, no 163 studies, in West Africa or elsewhere, have tested the impact of multiple micronutrient-fortified 164 bouillon on micronutrient status. 165 166 Study objectives 167 The primary objectives are to assess the effects of household use of multiple 168 micronutrient-fortified bouillon cubes (containing iodine in addition to vitamin A, folic 169 170 acid, vitamin B12, iron, and zinc), compared to control bouillon cubes (fortified with iodine only), on micronutrient status and hemoglobin concentrations among non-171 pregnant, non-lactating women 15-49 years of age (referred to hereafter as women of 172 reproductive age, WRA) and among children 2-5 years of age, and breast milk 173 micronutrient concentrations among non-pregnant, lactating women 15-49 years of age at 174 175 4-18 months postpartum (hereafter, lactating women).

1	7	6
_		v

170	
177	Secondary objectives include the effect of the multiple micronutrient-fortified bouillon,
178	compared to the control bouillon, on the prevalence of micronutrient deficiencies and anemia;
179	dietary intake of bouillon and micronutrients; inflammation, malaria, and morbidity symptoms;
180	and children's anthropometric measures and child development (details of primary and
181	secondary outcomes for each physiological group are listed in supplemental material S1 and S2).
182	Sub-studies will also assess opinions, attitudes, and acceptance (OAA) of the multiple
183	micronutrient-fortified bouillon and hypothetical willingness-to-pay (WTP) for multiple
184	micronutrient-fortified bouillon.
185	
186	We generally hypothesize that micronutrient status, hemoglobin concentrations, dietary nutrient
187	intake, child growth, and child development scores will be greater, and that prevalence of each
188	micronutrient deficiency, anemia, and inflammation and morbidity will be lower, among
189	participants who receive the multiple micronutrient-fortified bouillon compared to those who
190	receive the control bouillon. Specific hypotheses will be reported in statistical analysis plans that
191	will be posted prior to data analysis.
192	
193	
194	Materials and Methods
195	
196	The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-African Clinical Trial
197	Registry (PACTR202206868437931). The full study protocol and statistical analysis plans are
198	posted on Open Science Framework (https://osf.io/t3zrn/).
199	

199

200 Study design

201 This community-based trial will follow a randomized, controlled doubly-masked design. WRA 202 (n=1028), children (n=690), and lactating women (n=690) will be recruited from households in selected communities within the Kumbungu and Tolon districts, Northern Region, Ghana. The 203 204 flow of study activities for each of the 3 physiological groups, and summary of exclusion and deferral criteria, are illustrated in Figure 1, while the schedule of data collection is summarized 205 in **Table 1**. Written informed consent will be obtained from participating women and from 206 caregivers of participating children. Consented WRA will be invited for a screening visit for 207 assessment of total body vitamin A stores using the retinol isotope dilution (RID) technique [24]. 208 Following a 3-week observation period, which includes 2 in-home visits, all participants will 209 undergo baseline assessment, and eligible participants will be enrolled by being randomly 210 211 assigned to receive household rations of one of two types of bouillon cubes: 1) a multiple 212 micronutrient-fortified bouillon cube containing vitamin A, folic acid, vitamin B12, iron, zinc, and iodine, or 2) a control cube fortified only with iodine. Households will be advised to prepare 213 their meals as usual, but will be requested to use the study-provided bouillon instead of the 214 commercially available bouillon they typically purchase. Households will then be visited every 2 215 weeks for delivery of study cubes, monitoring of adherence, and recording of morbidity 216 217 symptoms. Endline assessments will be conducted after ~9 months (35 and 38 weeks) for WRA and children, and after ~3 months (11 and 12 weeks) for lactating women. Details of study 218 procedures and data collection at each time point are summarized in Table 1 and below. 219

220

221 Figure 1. Flow of study activities.

223 Table 1. Schedule of recruitment, screening, enrolment, intervention, and assessments.

Type of data collection			Screening (WRA)	Observation period	Baseline	Intervention Period					Study
						Initial	Biweekly	4-weekly	Endline 1	Endline 2	check-out
ENROLLMEN	Г			<u> </u>		1				•	1
	Household eligibility	х									
	Individual eligibility	х	Х		Х						
	Informed consent	Х									
	Retinol isotope dosing (WRA)		Х						X		
	Enrollment				Х						
	Study group allocation				Х						
INTERVENTIO	DN									•	
	Bouillon provision										
	Adherence monitoring						х				Х
ASSESSMENT	S			1 1		1					
Household data	collection										
	Demographics, SES	X									
Н	Iousehold bouillon KAP	x		x		x	х				X
	FACT	x				x		х			
	Willingness to pay	x									Х
	Opinions, attitudes, acceptance ¹			x		x (+ 60 d)					x (-60 d)
I	Food and water security	Х				X		х			
Index participar	nt data collection									·	
Anthropometry											
	MUAC	x			Х				х		
L	ength, weight, waist and hip circumference				Х				x		
Morbidity											
	Health history			X		х					
	Blood pressure		Х		Х				х	Х	
	Morbidity surveillance	x	Х	x		х	x				х
Blood sample co	ollection			· ·		•	•	•	•		•
	Hemoglobin		Х		Х				x	х	

	Hematocrit									
				Х				Х	Х	
	Infection indicators (malaria, CRP, AGP)	x		х				х	х	
	Vitamin A isotopes (WRA)			X					Х	
	Micronutrient status indicators (plasma ferritin, sTfR, zinc, RBP, retinol, B12; whole blood folate, plasma/serum folate, ZPP)			x				X	X	
Urine sar	nple collection	•		•		•		•	•	•
	HCG (WRA)	X						Х		
	Iodine, sodium	Х		х				Х		
Breast m	ilk sample collection		•	•				•	•	•
	Micronutrient status indicators (vitamin A, B12)			x				x	х	
Stool san	ple collection	•				•		•		1
	Inflammation indicators (calprotectin)			x				x		
	Microbiome			Х				х		
Dietary	· · ·	·				·		·	•	
	Food frequency questionnaire				Х		Х			
	24 h recalls		X		x (+ 30 d)					x (-30 d)
Child dev	velopment	I		<u> </u>				I	<u> </u>	<u> </u>
	Home inventory		x							x (-21 d)
	MDAT		X							x (-21 d)
	YET		X							x (-21 d)
				1						

¹ In addition, one round of focus group discussions will be conducted during the intervention period among a subset of participants in the OAA substudy. AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein;

EYT, Early Years Toolbox; FACT, Fortification Assessment Coverage Tool; HCG, human chorionic gonadotropin; KAP, knowledge attitudes and practices; MDAT, Malawi Developmental Assessment Tool;

MUAC, mid-upper arm circumference; RBP, retinol-binding protein; SES, socioeconomic status; WRA, women of reproductive age; ZPP, zinc protoporphyrin.

229 Study site

This proposed research will take place in the Tolon and Kumbungu districts in the Northern 230 Region. Micronutrient biomarker data from a pilot survey in these districts (not yet published) 231 confirmed prior research [10] that suggests micronutrient deficiencies are common. For example, 232 pilot data indicated that 28% of WRA and 53% of children 2-5 years of age were iron deficient 233 (serum ferritin concentration ≤ 15 or $\leq 12 \mu g/L$, respectively, adjusted for inflammation). In 234 addition, 34% of children had evidence of vitamin A deficiency (serum retinol <0.70 µmol/L, 235 adjusted for inflammation) although only ~1% of WRA had serum retinol <0.70 µmol/L. Serum 236 237 vitamin B12 concentrations were low (<221 pmol/L) among 12% of women and 19% of children 2-5 y, while low vitamin B12 concentrations in breast milk (<221 pmol/L) were observed among 238 40% of lactating women. Anemia was also common among both women (31%) and children 2-5 239 240 years of age (36%). Consumption of micronutrient supplements of any type was rare, with fewer than 10% of WRA and children interviewed in the pilot survey reporting consumption in the 241 242 previous 30 days. Similarly, pilot survey data also confirmed inadequate compliance with mandatory target micronutrient fortification levels of industrially fortified foods. Data on 243 micronutrient levels in food samples collected at the study site indicate that oil samples were 244 245 fortified with amounts equivalent to ~69% of target vitamin A levels and wheat flour samples were fortified with ~33-34% of target levels for iron and zinc (not yet published). 246

247

248 Identification and recruitment of participants

Participants in the study will be 1) non-pregnant non-lactating WRA 15-49 years of age,
2) children 2-5 years of age, and 3) non-pregnant, lactating women 15-49 years of age at
4-18 months postpartum. Multiple participants may be recruited from the same household
if they represent different physiological groups (for example, a WRA and child 2-5 years
of age), but only one index participant (e.g., one WRA) from each physiological group

254	will be recruited from each household. A household is defined as a group of people who
255	recognize the same head of household, live together, and share living expenses and meals
256	(see S5. Supplemental Methods for full definition). Sub-study respondents will be 1)
257	OAA: an adult household member (\geq 15 years of age) who is not recruited in the trial,
258	and 2) WTP: the household member who is primarily responsible for making decisions
259	about bouillon purchasing.

260

Within the Tolon and Kumbungu districts, we will recruit potential participants from 16 recruitment sites composed of 14 "rural" (comprising both rural and semi-urban areas) and 14 urban Ghana Statistical Service designated sampling areas. Recruitment of each physiological group (WRA, children, lactating women) will be balanced within each recruitment site so that the final sample of participants in each physiological group represents a similar geographic area.

266

Households in selected recruitment sites will be identified through a random walk method with
door-to-door recruitment[25]. Trained enumerators fluent in English and the local language
(Dagbani) will approach households to assess eligibility, administer recruitment questionnaires,
and conduct the informed consent process.

271

272 Consent

Upon selecting a household to approach, enumerators will first obtain oral consent from the head of household to proceed with the interview and then will administer a series of questionnaires to assess interest in study participation and complete a household roster. The household roster will be used to identify potentially eligible individuals. If more than one potentially eligible individual per physiological group is present in the home (for example, if there are two children between 2-5 years of age), one individual per physiological group will be randomly selected

based on a Kish Table [26]. Potentially eligible participants will then complete the written 279 informed consent process, wherein enumerators read aloud the consent form in the preferred 280 language of the participant (English or Dagbani), concluding with an informed consent quiz to 281 confirm the participant's understanding of the study procedures. Informed consent will be 282 confirmed with a signature or thumbprint; impartial witnesses (community members not 283 affiliated with the study) fluent in English and Dagbani will be present for the consent process 284 285 for non-literate participants to ensure the information presented orally matches the written informed consent sheet. Caregivers will provide consent for children 2-5 years; participants 15-286 287 17 years who have never married and are living with their parents will provide assent and their caregiver will provide consent. After an index participant has consented to participate in the 288 study, respondents for the OAA and WTP sub-studies will be recruited. For the OAA sub-study, 289 290 enumerators will use the household's roster and a random number generator to randomly select 291 the OAA participant from all remaining adult household members (e.g., ≥ 15 years and not recruited into the RCT); one OAA participant will be recruited per household. Upon agreement 292 to participate in the OAA sub-study, the selected adult household member will provide written 293 informed consent. For WTP, the household member with primary responsibility for bouillon 294 purchasing (who may or may not be a participant in the RCT) will be asked to provide oral 295 consent to respond to questions to elicit their hypothetical willingness to pay for a fortified 296 297 bouillon cube.

298

299 Inclusion and Exclusion Criteria, and Deferral Criteria

Detailed descriptions of the research inclusion and exclusion criteria by physiological group and
at each stage of the study are included in S5. Supplemental Methods and summarized in Figure
Briefly, households will be eligible for recruitment if the household is willing to use the studyprovided bouillon cubes for the duration of the study and no one in the household i) is currently

304	participating in another research trial, ii) has a chronic medical condition requiring frequent
305	blood transfusions, or iii) has an allergy to ingredients in the bouillon cubes (shrimp, wheat,
306	milk, soy, eggs, celery, fish, or mollusc). WRA, lactating women, and children will be eligible
307	for inclusion if they i) do not have a severe acute or chronic illness, ii) are able to provide
308	informed consent, and iii) plan to remain in the study area for the duration of the study.
309	WRA must have a negative malaria rapid diagnostic test (RDT) result and C-reactive protein
310	(CRP) ≤ 5 mg/L at the RID screening visit, and hemoglobin (Hb) ≥ 8 g/dL at the screening and
311	baseline visits. Children must have mid-upper arm circumference (MUAC) of ≥11.5 cm at
312	recruitment, and Hb \geq 7 g/dL, weight-for-height z-score (WHZ) \geq -3 SD, and no bilateral pitting
313	oedema at baseline.
314	
315	Throughout the study, WRA and lactating women who report pregnancy, and lactating women
316	who report lactation cessation, will be excluded. Participants who present with COVID-19-
317	related symptoms, or malaria or elevated CRP (WRA screening visit only), will be required to
318	defer study assessments for 2-3 weeks (Figure 1; Supplemental Methods). At the RID
319	screening or baseline visits, if participants do not meet inclusion criteria after the deferral period,
320	they will be excluded.
321	
322	The following sections describe the sequence of study visits and procedures.
323	
324	Screening and baseline visits
325	Following recruitment and consent, WRA will visit the study site to be screened for eligibility
326	for the RID test for assessment of total body stores of vitamin A [24]. Then, during a 3-wk
327	observation period, descriptive information will be collected for all participants at two in-home

328 visits. Following the 3-wk observation period, all participants will visit the study site for baseline

assessments; eligible participants will be randomized to a treatment group. Procedures at eachvisit are summarized below.

331

RID screening visit for non-pregnant, non-lactating women of reproductive age

WRA will be screened for eligibility for the RID test using procedures described below.
Fieldworkers will assess participants for recent morbidity, vitamin A intake (e.g., liver or
supplements in the past 24h) and pregnancy (based on human chorionic gonadotropin in urine),
measure blood pressure and collect a capillary blood sample. WRA with no recent (past 72h)
morbidity or intake of vitamin A-rich foods (e.g., liver) in the past 24h, who have a negative
pregnancy test, Hb ≥8 g/dL, CRP <5 mg/L, and a negative malaria RDT result will receive an
oral dose of d6-labelled vitamin A (2 mg retinol equivalent, sourced from Buchem BV,

340 Apeldorn, Netherlands) in sunflower oil. The labelled vitamin A will be certified as food grade

341 (Food Chemical Codex IV) and approved by the Ghana Food and Drugs Authority. All WRA

342 who received the d6-labelled vitamin A dose will be invited to the biospecimen collection site 21

days after the isotope dose (based on Green et al., 2021 [27]) for a venous blood sample to assess

total body vitamin A stores using the RID technique. This 21-day visit will be scheduled to

345 coincide with the trial baseline visit (procedures described below).

346

347 Observation period

348 For all participants, during the ~3-week period between recruitment and the baseline visit (i.e.,

349 the observation period), information on participant and household characteristics, dietary intake,

morbidity, and bouillon use will be collected during two household visits conducted 2 weeks

apart. Baseline child development assessments will also occur during this period. Additionally,

352 OAA participants will complete a demographic questionnaire and one quantitative survey about

353 opinions, attitude, and acceptance of commercial bouillon.

354

355 Baseline visit

After completion of the observation period, eligible participants will be invited to the mobile 356 biospecimen collection site for the baseline visit (Figure 1; Table 1). Following morbidity 357 358 screening, participants will undergo baseline data collection procedures, including anthropometry, measurement of blood pressure and collection of a spot urine sample (WRA and 359 children only), and collection of a stool sample (children only). Venous blood will be collected 360 from WRA (fasted) and children (nonfasted) for assessment of hemoglobin, malaria, and 361 biomarkers of micronutrient status and inflammation. For lactating women, a full breast milk 362 sample will be collected for micronutrient analysis. Questionnaires will be used to collect 363 individual level information related to the interpretation of biospecimen results. 364 365 366 Following the baseline data collection procedures, households with participants who remain eligible for the study will be randomized to a study arm; an enumerator will visit the household 367 on the following day (the initial home visit) to deliver the first ration of bouillon cubes that 368 369 corresponds to the assigned treatment group.

370

371 Randomization and blinding

The unit of randomization will be at the household level, regardless of the number of individual participants (up to 3) eligible within that household. To randomize the households, the trial statistician will create a computer-generated block randomization scheme with randomly selected block lengths of four or eight. Pieces of paper bearing intervention group assignments represented by 4 different 3-digit alphanumeric codes (2 codes per study arm) and numbered 1– 2408 (maximum number of households if each participant resides in a different household) will be placed in opaque envelopes and stacked in increasing order by study staff not involved in the randomization process. For each household enrollment, a designated and trained study personnel
will select the four topmost envelopes from the stack and ask the participant to choose an
envelope to reveal their study group assignment. At this point, the household ID (and the
participant IDs for each eligible participant within the randomized household) will be linked to
one of the four study codes indicating the intervention the household will receive.

384

All study bouillon cubes will be individually wrapped in identical packaging and will be identified only by the study code (a 3-digit alphanumeric code). Boxes of cubes will be labelled with the study code and an associated group color. Participants and study personnel will know the code (and for study personnel, the group color) to which each household is assigned but will not know the micronutrient content of the products.

390

Two code keepers (one at the University of California, Davis, UCD, and one at the University of 391 Ghana) who are not otherwise affiliated with the study will be responsible for assigning the 4 392 study codes to the intervention products and communicating directly with the manufacturer about 393 the group assignments. In addition, a hard copy of the randomization code will be stored in a 394 sealed envelope in a locked filing cabinet at the University of Ghana. Two individuals, 395 unaffiliated with the study, will have a key to the office and access to the key to the filing 396 cabinet. In the case of a severe adverse reaction pertaining to an individual participant, the 397 398 blinding code will be broken only to identify the bouillon cube formulation that the individual participant received, if necessary for their medical care. Only individuals directly involved in the 399 care of the study participant will be unblinded on a strict need-to-know basis. 400

401

The specific bouillon cube formulation associated with each of the 4 study codes will also bestored in sealed envelopes held by the co-principal investigators and the statistician. The

404 envelopes will be opened only after statistical analyses of the primary outcomes are completed405 and the investigators have reached consensus on interpretation of the results.

406

407 Intervention period procedures

Enumerators will visit participant households every 2 weeks throughout the study to provide the study bouillon rations and collect information on adherence (e.g., household inventory of study

410 bouillon and commercial bouillon, bouillon wrapper counts, bouillon use) and morbidity. All

411 reasonable efforts will be made to complete follow-up assessments, regardless of adherence.

412 Questionnaires to collect information on household food insecurity, water insecurity,

413 consumption of fortified foods, and dietary patterns (e.g., dietary diversity and child feeding)

414 will also be administered during the initial home visit and every 4 weeks thereafter (Table 1).

415 Cube delivery and data collection will be conducted with "no contact" methods (e.g., phone

416 interview) in the case of COVID-19 exposure or symptoms. Baseline dietary assessment will be

417 conducted by administering two 24-hour dietary recall interviews per participant on non-

418 consecutive days within 30 days after the baseline visit (all participants), and two additional 24-

419 hour dietary recalls will be conducted on non-consecutive days within the 30 days before the

420 second endline visit (WRA and children only).

421

Within the first two months of the intervention period, OAA participants will complete a similar
quantitative survey to that administered in the observation period but focused on the study-

supplied bouillon cubes, and again within the last two months of the intervention period. OAA

425 participants in households in which the only trial participant is a lactating woman will complete

426 only one intervention period survey.

428 Endline visits

At the end of the intervention period, participants will be invited to the mobile biospecimen 429 collection site for the two endline data collection visits (35 weeks and 38 weeks for WRA and 430 children; 11 weeks and 12 weeks for lactating women). A 3-week period between endline visits 431 432 was chosen based on the desired timing between the isotope dose administration and blood collection for assessment of total body vitamin A stores. Delivery of study bouillon cubes will 433 continue through the last endline assessment for each household. Data collection procedures at 434 the first endline visit will be similar to those described at the baseline visit. Briefly, data 435 collection will include anthropometric measurements and morbidity symptoms (all participants); 436 437 spot urine samples, blood pressure measurement and venous blood collection (WRA and

438 children); breast milk collection (lactating women); and stool collection (children).

439

In addition, at the first endline visit (35 wk), WRA will receive an oral dose of ${}^{13}C_{10}$ -retinyl 440 acetate (2 mg retinol equivalents, sourced from Buchem BV, Apeldorn, Netherlands) to assess 441 total body vitamin A stores. ¹³C₁₀-retinyl acetate will be used at endline to avoid any potential 442 interference from the baseline dose of d6-retinyl acetate. To assess eligibility for the endline 443 isotope dose, participants will undergo screening procedures identical to those at the pre-444 445 intervention screening visit, including assessment of morbidity symptoms, vitamin A intake, pregnancy (based on measurement of HCG in urine), anemia, malaria infection, and 446 inflammation. Based on results of these assessments, WRA will either be 1) eligible to receive 447 448 the endline isotope dose and continue with the study; 2), deferred and scheduled to be rescreened for isotope dosing at the 2^{nd} endline visit (recent morbidity, CRP > 5 g/L, positive 449 malaria RDT); 3) excluded from isotope dosing and the second endline blood collection 450 (participants with Hb < 8 g/dL), or 4) excluded from the study (positive pregnancy test) (see S5. 451 Supplemental Methods for detailed exclusion and deferral criteria). 452

454	Data collection procedures at the second endline assessment will include a subset of the
455	outcomes measured at the first endline assessment, measured using identical methods. These will
456	include morbidity symptoms (all groups), venous blood collection (WRA and children) and
457	breast milk collection (lactating women). WRA who are deferred at the first endline visit, and do
458	not receive the vitamin A isotope dose, will be re-screened at the second endline visit using the
459	same procedures for eligibility described above. WRA who are eligible to receive the isotope
460	dose at the second endline will be asked to return for an additional endline visit to collect a
461	follow-up venous blood sample for RID assessment 3 weeks later.
462	
463	In between the two endline visits (35wk and 38wk), a single endline child development
464	assessment will be completed for each task. After the second endline visit, a final home visit will
465	be conducted to complete the study exit form and collect all remaining study bouillon cubes from
466	the household. In each household, the baseline assessment of hypothetical willingness-to-pay for
467	a fortified bouillon cube will be repeated at endline.
468	
469	Intervention: Fortified bouillon development
470	Product formulation
471	Bouillon cubes for the trial will be produced based on a non-proprietary formulation that is
472	comparable to commercial cubes sold in Ghana, containing \sim 52% salt by weight, along with
473	palm fat, corn starch, spices and flavour enhancers, colouring, and micronutrient premix
474	(Nicholas Archer, CSIRO, personal communication). Shrimp flavour was selected, as it was the
475	primary bouillon flavour used by all households in the pilot survey in the study community [28].
476	Table 2 presents the micronutrient concentrations, chemical fortificant forms of each nutrient,
477	and equivalent daily target micronutrient doses for women and young children in the active arm

of the study. The specific fortificants were selected on the basis of technical compatibility with
the food matrix and experience with use as fortificants [29]. In the case of iron, the combination
of ferric pyrophosphate (FePP) with a citric acid/trisodium citrate buffer (CA/TSC) is expected
to enhance bioavailability compared to FePP alone [30].

482

With estimated typical bouillon consumption of 2-2.5 g/d among WRA and 1 g/d among 483 484 children, these cubes supply a daily dose of micronutrients equivalent to 33% to 133% of the corresponding US Recommended Daily Allowance for the 6 micronutrients added to the cubes 485 486 (Table 2). The concentrations of micronutrients were selected based on: 1) modelling of national survey data from Ghana and other West African countries to estimate the contribution of 487 hypothetical fortification of bouillon to adequacy of dietary micronutrient intake (to estimate the 488 potential public health benefit) [14]; 2) the estimated amount of bouillon consumed in the 489 490 communities selected for the study; 3) expected efficacy, based on a literature review of the effect of micronutrient interventions on change in micronutrient status as measured by 491 biomarkers or on clinical outcomes (anemia and neural tube defects) and estimated accumulation 492 of micronutrient stores (vitamin A and iron); and 4) safety considerations, including the 493 likelihood of study participants or their household members exceeding the tolerable upper intake 494 level (UL), and a review of the literature to identify adverse effects of micronutrient 495 interventions at varying daily micronutrient doses. Additional details on the rationale for the 496 497 selected fortification levels and estimated daily micronutrient doses are provided as a Technical Appendix to the study protocol (available at https://osf.io/t3zrn/). 498

499

500 The control cube formulation contains iodine but no other added micronutrients. This selection501 of micronutrient for the control cube is consistent with current policy in Ghana, where salt

iodization is mandated (15 mg/kg at household level) [31] and commercial bouillon cubes are
typically made with iodized salt [18].

504

505 Product testing

Acceptability of the unfortified, non-proprietary cube formulation was confirmed through 506 507 consumer testing in northern Ghana, including using commercial cubes as a reference (Nicholas Archer, CSIRO, personal communication). The effects of micronutrient fortification on 508 micronutrient stability and sensory properties of the multiple micronutrient-fortified bouillon 509 were evaluated in accelerated storage trials. The results confirmed good stability and cube 510 quality after 2 weeks of storage of bouillon cubes (in individual wrappers) under accelerated 511 storage conditions (37°C, 75% relative humidity), and for at least 5 months for storage under 512 optimal conditions (23°C, 50% relative humidity) (Nicholas Archer, CSIRO, personal 513 communication). Finally, acceptability of the multiply-fortified and control cube formulations 514 used in this study was evaluated among a sample of women and their households in the study 515 community [32]; overall, the study results suggested that the bouillon formulations were well 516 liked and would be suitable for use in further research studies. 517

518

519 Bouillon cube production and management

520 Bouillon cubes will be produced at industrial scale by GB Foods (Barcelona, Spain). Bouillon

521 cubes will be shipped by air or sea to Ghana and transported to a dedicated storage facility at the

study site. Boxes of bouillon will be stored on pallets in a cool $(12 - 16^{\circ} \text{ C})$ temperature-

523 controlled environment with frequent temperature and humidity monitoring. Micronutrient

524 content of the micronutrient premix and the study bouillon cubes will be analyzed to ensure

- 525 proper coding and formulation of the bouillon cubes before distribution to participants.
- 526

527 Table 2. Target fortification levels, estimated daily dose of micronutrients delivered by

528 fortified bouillon, and percent of the recommended daily allowance for women of

529 reproductive age and young children¹

530

Micronutrient (Fortificant)	Amount of micronutrient per gram bouillon ²	Daily amount provided to women ³	Daily amount provided to women, as proportion of the RDA	Daily amount provided to children	Daily amount provided to children as proportion of the RDA
Vitamin A (retinyl palmitate)	200 µg	400 - 500 μg	57 - 71%	200 µg	50 - 67%
Folic acid	80 µg	160 - 200 µg	67 - 83%	80 µg	67 - 89%
Vitamin B12	1.2 µg	2.4 - 3.0 μg	100 - 125%	1.2 μg	100 - 133%
Iron (FePP/CA/TSC)	4 mg	8 - 10 mg	44 - 56%	4 mg	40 - 57%
Zinc (ZnO)	3 mg	6 - 7.5 mg	75 - 94%	3 mg	60 - 100%
Iodine (KIO ₃)	30 µg	60 - 75 μg	40 - 50%	30 µg	33%

¹Recommended Daily Allowance (RDA) values are for women 19-50 years of age and children

1-3 y and 4-8 y [33]. FePP/CA/TSC: ferric pyrophosphate/citric acid/trisodium citrate. Values do
not include overage. Overages based on expert opinion were added to account for losses during
storage and cooking (30% vitamin A, folic acid, and vitamin B12; 20% iodine; 0% iron and
zinc).

²Values represent the amount of the active form of the nutrient, e.g. 200 μg retinol equivalents as
 retinyl palmitate and 4 mg iron as FePP/CA/TSC.

³Range of values reflects assumed bouillon cube intake of 2-2.5 grams per day among WRA. For
 children, calculations assume 1 gram per day and RDA categories of 1-3 years and 4-8 years of
 age (representing children 2-5 years of age).

541

- 542 Household bouillon ration
- 543 The household bouillon ration will be determined based on household size and estimated

544 bouillon consumption (2.5 g/capita/d). This approach was based on previous research in the

- study community showing that median per household bouillon consumption was 20 (12, 24) g/d
- 546 (median, p25, p75) and that bouillon consumption was 2.4 g/d among WRA and 1.0 g/d among
- children, similar to the assumptions in Table 2 [28]. The household bouillon ration may be
- revised over the course of the study based on observations and questionnaire responses (e.g.,
- changes to household composition) but will not exceed 4 g/capita/d. Bouillon rations will be
- delivered by enumerators to participants' homes every 2 weeks and stored in study-provided

plastic containers. Households will be encouraged to use the study bouillon (in lieu of commercially purchased bouillon cubes) according to their typical cooking habits. At the initial home visit (first day of bouillon distribution) only, the enumerator will request to collect all commercial bouillon in the household; if the household agrees, they will be compensated according to a table of current brand-specific market prices for bouillon. During the trial, households are free to purchase and use commercial bouillon cubes as they choose.

557

558 Data collection methods

559 Questionnaires

Trained enumerators will administer all questionnaires in the preferred language of the 560 participant (English or Dagbani) as structured oral interviews using electronic tablets. Data on 561 562 demographic and socio-economic status (household size and composition, assets, housing quality, sanitation and hygiene, and individuals' education and occupations), food security 563 [Household Food Insecurity Access Scale (HFIAS) [34]] and water security [Household Water 564 565 Insecurity Experiences (HWISE) [35]] will be collected. Pilot-tested questionnaires will also 566 collect information on household bouillon acquisition, consumption, and stocks; bouillon knowledge, attitudes and practices (KAP); consumption of fortified foods, including bouillon 567 568 [Fortification Assessment Coverage Tool (FACT)[26]; and hypothetical willingness-to-pay (WTP) for a new micronutrient-fortified bouillon cube. Information on health history, non-569 communicable disease risk [WHO STEPwise approach to NCD risk factors surveillance 570 (STEPS) questionnaire] [36], and breastfeeding and infant and young child feeding practices 571 (IYCF) [37] and dietary diversity (Dietary Quality Questionnaire [DQQ]) [38] will also be 572 collected. Parent perception of child weight and parental beliefs, attitudes and practices toward 573 574 child feeding will be assessed with a child feeding questionnaire (CFQ) [39]. Structured

questionnaires will be used to assess recent morbidity (presence and severity of selectedsymptoms of pre-defined diseases and serious adverse events).

577

578 Adherence

Households will be requested to save wrappers from all bouillon (both study-provided and 579 commercial) used in the household since the last biweekly visit. To monitor adherence, at each 580 581 biweekly visit during the intervention period, enumerators will count the bouillon wrappers and record an inventory of all bouillon cubes in the household (both study-provided and 582 commercial). In addition, enumerators will administer a questionnaire to gather data about 583 584 household purchases of bouillon and household bouillon use in the past 2 weeks, including sharing of study bouillon cubes with non-household members. Households with sustained low 585 adherence (i.e., low consumption of study-provided bouillon) will be identified through routine 586 587 adherence data monitoring; enumerators will be instructed to inquire about the reasons for low adherence and to encourage use of the study bouillon. 588

589

590 24 hour recalls

Quantitative dietary intake data will be collected through 24-hour dietary recall interviews to capture bouillon and nutrient intake both prior to and while receiving the study cubes. All participants (WRA, lactating women, children) will complete one dietary recall during the observation period and two baseline dietary recalls on non-consecutive days within the first 30 days of the intervention period. WRA and children will complete two additional endline recalls on non-consecutive days within the 30 days before the second endline visit. Lactating women will not complete endline dietary recalls due to the shorter study duration.

598

Dietary recalls will be conducted by enumerators with extensive training and practice on the 24-599 hour recall technique. Interviews will follow a multiple pass methodology [40] to collect 600 information on all foods and beverages consumed by each participant during a defined 24 hour 601 period. Recall data will be collected using a tablet-based data collection system (an adaptation of 602 OpenDRS [41]) that allows for direct entry of dietary data and recipe collection on the tablet, 603 through a platform that guides interviewers through the dietary recall interview and suggests 604 605 prompts to aid in the interview process. Dietary recalls will be conducted in participant households to take advantage of the opportunity to use the participants' typical utensils for 606 607 portion size estimation where possible. Enumerators will also carry "kits" with common utensils and foods (e.g., salt, sugar, spices, etc.) to obtain weights for portions and ingredients where 608 possible. 609 610 Opinions, attitude, and acceptance (OAA) towards the study bouillon among adult household 611 members 612 The OAA sub-study will employ a mixed methods approach (quantitative survey and focus 613 614 group discussions). OAA towards commercial bouillon will be evaluated with a questionnaire during the observation period, and towards the study-provided bouillon with a similar 615 questionnaire once within the first 60 days and once within the final 60 days of the intervention 616 period. One round of focus group discussions (FGDs) will also be conducted among a subset of 617 participants who complete the OAA questionnaires to qualitatively assess OAA of the study-618 supplied bouillon cubes. FGDs will be conducted in Dagbani following a pre-tested FGD guide 619 and audio-recorded. 620

622 Anthropometry

623	Anthropometric data will be collected by trained, standardized anthropometrists, following
624	protocols established by the Food and Nutrition Technical Assistance Project [42]. Children's
625	MUAC (left arm; UNICEF S0145620), standing height of all participants (SECA 217), and the
626	waist and hip circumference of WRA (SECA 201) will be measured to 0.1 cm precision. Weight
627	of all participants (lightly clothed) will be measured to 50 g precision (SECA 874). All
628	measurements will be collected in duplicate, and the average of the two measurements calculated
629	per participant for each outcome. If the two measurements differ by more than 0.1 kg (weight),
630	or 0.5 cm (MUAC, height, waist or hip circumference), the measurement will be repeated, and
631	the two closest measurements will be retained for data analysis.
632	
633	Child development
634	Child development will be assessed with the Malawi Development Assessment Tool (MDAT)
635	[43], which measures four domains of development (gross motor, fine motor, language, and
636	personal-social), and the tablet-based Early Years Toolbox Go-No-Go Task which measures
637	executive function (EYT) [44]. Assessments will take place at a central data collection site or (if
638	necessary) in a low-distraction location at the participant's home. Characteristics of the home
639	environment and caregiver-child interaction will be assessed at a household visit with the Home
640	Observation Measurement of the Environment (HOME) tool [45]. To assess the test-retest
641	reliability of the EYT a convenience sample of 30 children will be asked to come back 1 week
642	later to repeat the EYT.
643	
644	Prior to data collection, enumerators trained in child development assessment will be required to
645	take a written and practical assessment on the data collection procedures. Inter-rater reliability of

646 the enumerators will be assessed for the MDAT and the HOME to ensure consistency of data

647 collection. The MDAT and HOME were previously piloted in the study site and found to be648 feasible for use in this setting.

649

650 Biological sample collection and laboratory analyses

651 *Capillary and venous blood collection*

652 At the pre-intervention RID-screening visit, capillary blood samples will be obtained from WRA

to measure hemoglobin and CRP concentrations using the QuikRead Go (Aidian Oy, Espoo,

Finland); malaria antigenemia will be measured by RDT (BioZEK, B.V., Apeldoorn,

Netherlands). At the post-intervention RID-screening visit, these measurements will be done

using venous blood that is collected for assessment of endline micronutrient status.

657

At baseline and endline assessments, venous blood samples will be collected from children and 658 WRA by trained laboratory technicians, following standard biological safety protocols and 659 procedures recommended by the International Zinc Nutrition Consultative Group (IZiNCG) [46]. 660 Samples will be collected at a central location in each community (mobile biospecimen 661 collection site) in the early morning. WRA, but not children, will be asked to fast for at least 8 662 663 hours prior to their blood draw appointment; time of blood collection and last meal will be recorded for all participants. At all blood sample events (baseline, endline 1 and endline 2), 7.5 664 ml of blood will be drawn from the antecubital vein into an evacuated, trace element-free 665 polyethylene blood collection tube containing lithium heparin (Sarstedt AG & Co, Numbrecht, 666 Germany; ref 01.1604.400). For all WRA at baseline and endline 2, as well as a subset of WRA 667 at endline 1, an additional 4.5 ml of blood will be drawn from the antecubital vein into an 668 evacuated serum blood collection tube (Sarstedt AG & Co, Numbrecht, Germany; ref 669 05.1104.100); this will occur prior to blood collection in the lithium heparin tube. In addition, if 670 WRA receive the vitamin A isotope dose at endline 2 (due to deferral), an additional 4.5 ml of 671

blood will be drawn from the antecubital vein into an evacuated serum blood collection tube 672 (Sarstedt AG & Co, Numbrecht, Germany; ref 05.1104.100) at a third time point. If the 673 phlebotomist is unable to obtain a venous blood sample after two attempts, a capillary sample 674 will be obtained by fingerstick and collected into a 200 µl microvette containing lithium heparin 675 (Sarstedt AG & Co, Numbrecht, Germany; ref 20.1292.100). Following blood collection, all 676 blood collection tubes will be placed into a battery-operated cold box $(4 - 8^{\circ}C)$ until processing. 677 678 Immediately following blood collection, point-of-care assessments will be performed using 679 680 whole blood remaining in the butterfly tubing or needle (or from the capillary sample); if necessary, whole blood may be aliquoted from the lithium heparin blood collection tubes for the 681 RDTs. Hemoglobin will be measured using a portable photometer (Hemocue 301, HemoCue 682 AB, Angelholm, Sweden). Malaria antigenmia will be assessed with an RDT. Hematocrit (WRA 683 only) will be measured using the GCH-24 Hematocrit centrifuge (Globe Scientific, Mahwah, 684 New Jersey, USA). In addition, hemoglobin, hematocrit and zinc protoporphyrin (ZPP) will be 685 measured using the iCheck Anemia point-of-care device (Bioanalyt, Teltow, Germany). 686 687 Whole blood samples from the serum blood collection tubes will be allowed to clot for 30-60 688 minutes, after which time they will be centrifuged at 1097 x g (3100 RPM) for 10 minutes 689 (PowerSpin Centrifuge Model LX C856E; United Products & Instruments, Inc, Dayton, NJ). 690 Serum will be aliquoted for the measurement of concentrations of [¹²C]retinol, d6-retinol and 691 $[^{13}C_{10}]$ retinol and folate. From the lithium heparin blood collection tube, 100 µl of whole blood 692 will be aliquoted into a cryovial containing 1 ml of 1% ascorbic acid solution for the 693 694 measurement of folate concentration (to calculate erythrocyte folate) among WRA. The remaining heparinized blood will be centrifuged within 8 h of collection at 1097 x g (3100 RPM) 695 for 10 minutes (PowerSpin Centrifuge Model LX C856E; United Products & Instruments, Inc, 696

697 Dayton, NJ). Plasma will be aliquoted into cryovials for the measurement of micronutrient status

698 (i.e., ferritin, soluble transferrin receptor [sTfR], retinol binding protein [RBP], retinol, zinc,

699 folate and B12) and indicators of systemic inflammation (i.e., CRP, and alpha-1-acid

700 glycoprotein, AGP).

701

702 Breast milk collection and processing

At baseline and endline assessments, breast milk samples will be collected from lactating women 703 using the "full milk sample" methodology [47] using the Medela Swing single electric breast 704 pump (Barr, Switzerland). Breast milk will be collected from the breast from which the infant 705 has not fed for a longer time (i.e., the breast that is 'more full'), with a minimum of one hour 706 707 elapsed between the milk sample collection and previous feeding. Time of day and time since last feed will be recorded. Fat will be measured in fresh milk in triplicate using the creamatocrit 708 method (Creamatocrit Plus Centrifuge; EKF Diagnostics) [48]. The milk sample will be mixed 709 well and ~6 ml will be aliquoted for the measurement of vitamins A and B12; the remainder of 710 the milk sample will be returned to the lactating woman to feed to her child. 711

712

713 Urine collection and processing

Urine samples will be collected from both WRA and children at baseline and endline 1
assessments. Among WRA only, spot urine samples will be collected on the day of the pre- and
post-intervention RID-screening visits (prior to retinol isotope dosing) to assess pregnancy status
based on rapid tests for human chorionic gonadotropic (HCG). At all time points, urine will be
aliquoted into cryovials for the measurement of iodine, sodium, potassium and creatinine
concentrations.

720

721 Stool collection and processing

Stool samples will be collected from children at baseline and endline 1. The child's caregiver 722 will be provided with stool sample collection kits (self-standing transport tube with screw cap 723 and spoon, absorbent pad and/or diaper, gloves, biohazard bags, soap) and requested to collect 724 the first available fresh stool sample from the child on the morning of the baseline visit, partially 725 filling the transport tube. In a randomly selected subset of participants, caregivers will also be 726 727 provided with a stool nucleic acid collection and preservation tube (Norgen Biotek; Ontario, Cananda), and requested to collect a small sample of stool into a second tube. Unpreserved stool 728 729 samples will be aliquoted into cryovials for the measurement of calprotectin; no processing will be necessary for the microbiome analysis samples in the nucleic acid collection and preservation 730 tubes. 731

732

733 Biological sample storage

All biological sample aliquots will be stored in a battery-operated cold box (4 – 8°C) and transported daily from the biospecimen collection site to the District Hospital at Tolon for storage in a -86°C freezer, with regular temperature monitoring. Samples thus stored will be periodically transported to the University of Ghana for longer-term frozen storage before analysis. Samples to be analysed outside Ghana will be shipped by air on dry ice to the respective labs, as described below.

740

741 Laboratory analysis

742 Plasma ferritin, sTfR, RBP, CRP, and AGP concentrations will be measured in duplicate using a

combined sandwich enzyme-linked immunosorbent assay (ELISA) technique at VitMin Lab

(Willstaett, Germany) [49]. Serum concentrations of d6-retinol, $[^{12}C]$ retinol and $[^{13}C_{10}]$ retinol

vill be measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS) at

Newcastle University (Newcastle, UK) [50]. Plasma [51] and breast milk [52] vitamin A 746 concentrations will be measured by high performance liquid chromatography (HPLC) at the 747 UCD (Davis, CA). Plasma zinc concentrations will be analyzed by inductively-coupled plasma 748 optical emission spectrophotometry (ICP-OES; Agilent 5100 SVDV, Santa Clara, CA) at the 749 University of California, San Francisco (UCSF) Benioff Children's Hospital (Oakland, CA) [53]. 750 Whole blood folate and serum/plasma folate will be analyzed by the US Centers for Disease 751 752 Control and Prevention (Atlanta, GA) and used to calculate erythrocyte folate concentrations [54]. Vitamin B12 concentrations in plasma and breast milk, will be measured by the Western 753 754 Human Nutrition Research Center (Davis, CA). Urinary iodine concentration will be assessed using a modification of the Sandell-Kolthoff reaction at the University of Ghana [31]. Urinary 755 sodium, potassium and creatinine concentrations will be analyzed at the UCSF Benioff 756 757 Children's Hospital (Oakland, CA). Stool calprotectin will be analysed using a commercially 758 available kit and gut microbiota will be characterized by bacterial 16S rRNA sequencing at UCD (Davis, CA). Novel indicators and other indicators of micronutrient status, growth and infection 759 760 may be assessed if funding becomes available, among participants who consented to the use of their specimen for future research. 761

762

763 Data management and analysis

764 Data management and confidentiality

Data will be collected directly on tablets via forms developed to include pre-determined logic
checks and range validations using the SurveyCTO® program. Selected data collected on paper
forms will be double-entered. Data will be monitored daily by field supervisors. Weekly reports
for monitoring of key variables, including study enrollment, attrition, missing data/forms,
adherence, and selected quality control monitoring will be routinely reviewed by the research
team and field supervisors to identify action items (e.g., form corrections, refresher trainings,

participant visits to encourage adherence, data corrections, etc.). Study procedures are designed
so that all Personally Identifying Information is kept separately from all other data throughout
data collection, storage, and analysis and only accessible to a limited number of authorized
members of the research team.

775

776 Outcome definitions

For WRA and children, primary outcomes are hemoglobin concentrations and biomarkers of 777 status of iron (plasma ferritin and sTfR), zinc (plasma zinc), folate (plasma folate, erythrocyte 778 folate), vitamin A (total body stores of vitamin A [WRA only], serum retinol, plasma RBP), and 779 vitamin B12 (plasma B12) measured in venous blood samples. Pilot data indicated that vitamin 780 781 A deficiency was common among children but not WRA in the community; therefore, total body vitamin A stores were selected as the vitamin A outcome for WRA because serum retinol is 782 783 expected to respond to increased vitamin A intake only when vitamin A stores are low [55]. For lactating women, primary outcomes are concentrations of vitamin A (corrected for milk fat) and 784 vitamin B12 in human milk. Secondary outcomes for women and children include anemia and 785 786 prevalence of micronutrient deficiencies, malaria and inflammation (CRP and AGP), blood pressure and hypertension, and urinary iodine and sodium. Additional secondary outcomes 787 include dietary intake of bouillon and micronutrients, and morbidity symptoms (all participants); 788 low milk micronutrient concentrations (lactating women); and child development and stool 789 calprotectin (children). S1 and S2 (Supplemental Tables 1 and 2) include detailed lists of 790 primary and secondary outcomes, and S3 and S3 (Supplemental Tables 3 and 4) specify the 791 micronutrient biomarker cutoffs to be used. 792

793

794 Data analysis

Statistical analysis plans (SAPs) will be developed and posted publicly prior to conducting any 795 data analysis. For each analysis, a flow diagram for participation will be prepared according to 796 797 CONSORT guidelines. In most cases, separate analyses will be conducted for each physiological group. Because randomization will occur at the household level and only one individual per 798 physiological group will be enrolled per household, the participants will be considered 799 800 independent with repeated measurements on the same participant being accounted for with robust standard errors [56]. Additionally, a variable representing the recruitment site of each 801 802 participant will be included as a control covariate.

803

The primary analysis will be based on a complete-case intention to treat framework and analysed 804 805 as a pre-post study design, controlling for baseline measure of the outcome [57]. Testing will be 806 two-sided superiority testing. For continuous outcomes, this will follow an ANCOVA approach with non-normal outcomes transformed prior to analysis (typically log transformed). For binary 807 outcomes, we will use either logistic regression to estimate odds ratios or binomial log-link / 808 modified poisson regression to estimate risk ratios (approach will be pre-specified in each SAP). 809 In addition to the outcome-specific testing, certain analyses may use a multivariate analysis to 810 examine the simultaneous impact of the intervention on multiple outcomes (approach will be 811 812 pre-specified in each SAP).

813

In keeping with the randomized design of the study, we will rely on the minimally adjusted analysis (only controlling for baseline measure and recruitment site) as our primary analysis. For selected biomarkers (for example, plasma ferritin), the primary analysis will use inflammationcorrected outcomes and/or a minimally adjusted analysis that includes markers of inflammation (CRP and AGP) at each time point, if biologically relevant and if the outcome is associated with

the markers of inflammation in bivariate analyses (details will be pre-specified in each SAP). In
a secondary analysis, we will estimate adjusted parameters by including variables that are
strongly associated with the outcome to potentially improve the precision of our estimates (i.e.,
decrease the standard errors). Variable selection approach will be pre-specified in each SAP.
Additionally, pre-specified effect modification testing will be conducted by including an
interaction term in minimally adjusted models.

825

Substantial attrition (>20% loss) after randomization will trigger sensitivity analyses to assess the impact of missingness on inference. This will be conducted either by multiple imputation or inverse probability of censoring-weighted analysis (pre-specified in each SAP). We will also conduct a per protocol analysis using data on adherence to identify the subgroup of participants in "high compliance" households.

831

A qualitative SAP will also be developed for analysis of the OAA focus group data. FGD transcripts will be translated and transcribed to English by two independent parties. A codebook will be developed, and two researchers will independently code the transcripts with Cohen's Kappa used to assess intercoder reliability (ICR); transcripts with an ICR <0.6 [58] (less than moderate agreement) will trigger discussion and recoding. Selection of qualitative themes will occur through discussions with the greater research team.

838

839 Sample size

B40 Detection of an effect size of 0.26 SDs was selected based on calculations of the change in total body vitamin A stores among WRA and iron stores among women and children over the 9-mo trial duration; details are presented in the Technical Appendix to the study protocol, available at https://osf.io/t3zrn/). Assuming this effect size and a level of significance of α =0.05 with 80%

power we will target an analytic sample size of 234 per physiological group per intervention group.
Although this sample size calculation is based on analysis of a single cross-sectional measurement,
final models will incorporate a baseline measurement and repeated endline measurements to
provide additional statistical power.

848

Attrition will be accounted for at multiple time points due to the multi-staged study design involving recruitment, screening and baseline study visits prior to randomization to study group. Overall attrition rates were estimated using cross-sectional pilot survey data and are set at ~32% for children 2-5 y of age and lactating women and at 54% for WRA to account for additional participant exclusion due to pregnancy during the intervention period. Therefore, the recruitment targets will be 690 lactating women, 690 children 2-5 y of age, and 1028 WRA; each split evenly by intervention group.

856

857 Safety and ethics

858 Ethical and institutional approvals

859 This trial, including the investigational product, has been reviewed and approved by the Ghana

860 Food and Drug Authority (FDA, clinical trial certificate number FDA/CT/2213), the Ghana

Health Service Ethical Review Committee (GHS-ERC) (GHSERC ID: 024/11/21), and the

UCD, USA, Institutional Review Board (IRB) Human Subjects Committee (IRB ID: 1837253).

863 The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-African Clinical Trial

Registry (PACTR202206868437931). Any protocol modifications will be submitted to the FDA,

865 GHS-ERC, and UCD IRB for review, and the trial registries will be updated with approved

866 modifications.

We will seek permission from the Regional (Northern Region) and District (Tolon and
Kumbungu) Directors of Health of Services as well as community leaders before recruiting
participants into the study. With the assistance of the local health personnel, we will then hold
general informational meetings with community leaders of each of the communities in the
catchment area about the objectives, methods and possible benefits of the study for the study
participants and communities.

874

875 Safety monitoring

A Data and Safety Monitoring Board (DSMB) will be established for this project. The board will 876 consist of 5 members (3 in Ghana, 2 international) not otherwise involved in this study, without 877 competing interests, and who are experts in child health and nutrition research (with one or more 878 members with expertise in medicine, infectious disease, and/or biostatistics). The DSMB will 879 880 meet at predefined intervals (with intermediate meetings added if deemed necessary by the committee or investigators) to review study progress (including recruitment, loss to follow up, 881 and protocol compliance) and safety monitoring data. The DSMB may recommend actions or 882 modifications, which will be addressed by the study investigators, who will then notify and/or 883 seek approval from the relevant ethical review committees, as appropriate. Blinded interim 884 analysis of severe adverse adverts (SAE) and selected adverse events (AE, such as diarrhea and 885 malaria) will be conducted for safety considerations and reviewed by the DSMB. No interim 886 analyses related to intervention efficacy are pre-planned. 887

888

The GHS-ERC, Ghana FDA (which regulates clinicals trials in Ghana), UCD IRB, or the DSMB
may request unblinded safety data to discuss in closed sessions. Unblinding of the intervention
group may be requested if there is a pattern of SAEs which may be related to study treatment

where the DSMB or other regulatory agency feels there is "potential for harm". In this case, therandomization code will be provided by one of the two code keepers.

894

Suspected SAEs, such as deaths or hospitalization of study participants, will be reported
immediately to the principal investigators, who will notify the GHS-ERC, the Ghana
FDA, the UCD IRB, and the DSMB in a timely manner as required by their policies;
these agencies and committees will then determine whether modifications are required to
ensure participant safety and welfare.

900

To minimize chance of exposure to COVID-19, we have developed Standard Operating 901 Procedures for our field staff and study participants based on recommendations by the 902 Government of Ghana and the GHS-ERC. A physician assistant will refer participants for 903 904 medical advice and treatment if they are found to have severe malnutrition (children), severe 905 anemia (children or WRA), malaria infection (children or WRA), hypertension (WRA), or other signs of severe illness. Morbidity will be monitored at biweekly home visits and participants 906 907 will be referred for follow up treatment based on symptoms reported during these visits. The cost of the national health insurance annual premium will be covered for all randomized 908 participants. 909

910

Participants who become pregnant will be excluded from the study for scientific reasons (effects
of pregnancy on micronutrient biomarker concentrations, and lack of validation of the RID
method for pregnant women). Although exclusion of study participants due to pregnancy is not
based on any safety concerns, we will follow all index participants who become pregnant until
the resolution of their pregnancy (miscarriage, still birth, live birth, etc.) via telephone interview
to monitor pregnancy outcomes.

917

918 Trial management

The trial will be implemented by investigators at the University of Ghana and UCD, who jointly 919 920 developed the trial protocol and all data collection procedures and instruments. Data collection staff will be hired by the University of Ghana, including supervisors, anthropometrists, 921 phlebotomist and laboratory staff, nurse, medical assistant, enumerators, an information 922 technology manager, data entry clerks, and an inventory manager. Staff will participate in 923 intensive training on research ethics, the study protocol, and data collection procedures, 924 925 including didactic sessions with accompanying quizzes, demonstrations, and pilot-testing. UCD staff will support the study implementation through in-person supervision and remote data 926 monitoring. Investigators from both universities meet weekly to discuss study progress. As the 927 928 trial is subject to audit at the discretion of the Ghana FDA, the study investigators have contracted with a Local Monitor who is responsible for conducting Good Clinical Practices 929 930 training of field staff, assessing and approving site readiness to begin data collection, and conducting regular visits to the study site to monitor study implementation. The Regional 931 (Northern Region) and District (Tolon and Kumbungu Districts) Directors of Health were 932 933 informed about the project on a regular basis throughout pilot research conducted in 2020-2022, and these interactions will continue through trial implementation and results dissemination. 934

935

This study is part of a larger initiative supported by the Bill & Melinda Gates Foundation that is
focused on generating evidence to inform discussions of bouillon fortification policy among
countries in West Africa. Helen Keller International received support from the Bill & Melinda
Gates Foundation for research and policy engagement activities related to bouillon fortification
in West Africa (INV-007916), that includes supporting the activities of multi-stakeholder
bouillon Country Working Groups in Nigeria, Senegal, and Burkina Faso. Helen Keller

International also administers a subaward to UCD for conduct of this trial as well as a portfolio 942 of modelling research focused on estimating the impacts, costs, and cost-effectiveness of 943 micronutrient-fortified bouillon. The larger initiative includes research on technical aspects of 944 bouillon fortification by the Commonwealth Scientific and Industrial Research Organisation 945 (CSIRO) and Research Institutes of Sweden AB (RISE), in collaboration with a consortium of 946 representatives of companies involved in production of bouillon or micronutrient fortificants. 947 948 These consortium partners developed the non-proprietary unfortified bouillon cube which served as the base formulation for the multiple micronutrient-fortified cubes tested in this trial. All 949 950 members of this large initiative were given the opportunity to review the study protocol and provide comments. However, the trial investigators selected the micronutrient levels in the 951 investigational bouillon cubes and retain all final decision-making authority related to all aspects 952 953 of study design, implementation, and dissemination (subject to requirements of the Ghana FDA 954 and ethical committees). Regular updates on study progress will be provided to consortium partners through email and virtual meetings. 955

956

957 Dissemination

958 The results from this study will be disseminated in national and international conferences and published as Open Access publications in peer-reviewed journals. Authorship will be determined 959 based on international criteria [59]. Dissemination workshops will be held with national 960 961 stakeholders in Ghana, and with regional and district stakeholders in the study area. Study results will also be disseminated through the network of bouillon-related partners and stakeholders 962 associated with this project, with particular focus on the West Africa region. Specific 963 dissemination activities will be informed by discussions of the trial Dissemination Advisory 964 Group, convened by University of Ghana, UCD, and Helen Keller International, and consisting 965 of representatives from academia and the public sector in Ghana, Burkina Faso, Senegal, and 966

967 Nigeria. Publications, Statistical Analysis Plans, and other study resources will be posted on
968 Open Science Framework (https://osf.io/t3zrn/).

969

970 Trial status

971 Recruitment began on January 16, 2023. Data collection is expected to be completed in mid-

972 2024.

973

974 Discussion

975

The burden of micronutrient deficiencies continues to be unacceptably high in many parts of the 976 world. In West Africa, bouillon fortification has the potential to reduce this burden. This study 977 will generate the first information on the effects of micronutrient-fortified bouillon cube on the 978 micronutrient content of human milk and the micronutrient status of women and young children, 979 980 populations that are vulnerable to micronutrient deficiency. As such, the study serves as "proof of concept" regarding the potential efficacy of micronutrient-fortified bouillon to achieve 981 adequate micronutrient status and reduce the consequences of deficiency. This information will 982 983 be useful to national, regional and global stakeholders involved in assessing the potential for fortified bouillon cubes to contribute to addressing deficiencies in one or more of the 984 micronutrients examined. 985

986

Research and policy discussions related to bouillon fortification must consider the
generalizability of study results, with specific attention to the 1) study population diets and other
characteristics, 2) micronutrient concentrations in the fortified bouillon, and 3) differences
between research and programmatic/commercial contexts for bouillon. The trial is being

991 conducted in a community with frequent bouillon intake and high prevalence of micronutrient

deficiency, and the micronutrient concentrations of the cubes tested in this trial were selected as
those likely to be both efficacious (i.e., increasing micronutrient status) and safe (i.e. not causing
adverse effects) in this context. While these characteristics also apply to many communities
throughout West Africa, there is great variation within and across countries in bouillon
consumption and micronutrient deficiency [14, 16]. Discussions on bouillon fortification
standards must consider the impacts on population subgroups with both adequate and inadequate
micronutrient intake, and populations with varying bouillon consumption.

999

1000 Where countries move ahead with bouillon fortification standards (or at the regional level, as cooking oil and wheat flour fortification are implemented in West Africa), decisions around 1001 selection of the desired micronutrient concentrations in the standards should use population-1002 1003 specific data on dietary intake as a starting point [29] rather than the levels tested in this trial. 1004 Micronutrient concentrations in standards may be different than those tested in this study, and standards may also include micronutrients that were not tested in this study. Modelling of 1005 1006 dietary intake or household consumption surveys data can help inform what micronutrients and what concentrations will meet dietary gaps for target population subgroups while minimizing 1007 intakes above the UL [60]. Standards must also consider technical and commercial constraints, 1008 such as required changes to product formulas and manufacturing processes, premix cost, and the 1009 1010 ability to pass along some or all of these costs to bouillon consumers. Moreover, it is important 1011 to note that in the trial context we are maintaining bouillon cubes in climate-controlled storage 1012 conditions (up to the point of delivery to the household) to ensure acceptability and micronutrient stability of the cubes; these characteristics will have to be confirmed under commercial 1013 1014 conditions.

1015

1016 In this trial, bouillon is regularly delivered to participant households, free of charge. The 1017 household bouillon ration is capped to avoid extra-household sharing and artificially inflating the impact of fortified bouillon if bouillon consumption were to increase due to providing bouillon 1018 free of charge to participating households. Nevertheless, in a program setting the effects of 1019 1020 fortified bouillon may be diluted if less-expensive, unfortified bouillon products are available or if households reduce their bouillon consumption in response to price increases due to 1021 1022 fortification. Moreover, program compliance with standards is a challenge with other types of large-scale food fortification programs [11] and especially for easily imported products, therefore 1023 1024 highlighting the need for effective monitoring and evaluation programs to secure the effectiveness of any future bouillon fortification programs. 1025 1026 1027 Given the wide and equitable reach of bouillon in West Africa, including among populations at 1028 risk of micronutrient deficiencies who do not consume other fortified foods, addition of micronutrients to bouillon holds great potential to reduce deficiencies. This study will provide 1029 1030 evidence regarding the efficacy of bouillon fortification in a specific West African context for improving micronutrient status. This new evidence will inform ongoing discussions on large-1031 scale food/condiment fortification and other strategies to reduce the burden of micronutrient 1032 1033 deficiencies and their consequences in the region.

1034

1035 Acknowledgments

We gratefully acknowledge the contributions of the local medical monitor Dr. Mohammed Hafiz
Kanamu (Tamale Teaching Hospital) and the local study implementation monitors Michael Ntiri
and Morrison Asiamah. We thank Dr. Bess Caswell (USDA Western Human Nutrition Research
Center) and Boateng Bannerman (University of Ghana, Legon) for assistance with study blinding
and Professor Sam Newton (Kwame Nkrumah University of Science and Technology (KNUST)),

Dr. Justice Moses K. Aheto (University of Ghana, Legon), Dr. Edward Frongillo (University of
South Carolina), Dr. Agartha Ohemeng (University of Ghana, Legon), and Prof Andrew
Prendergast (Queen Mary University of London) for serving on the Data and Safety Monitoring
Board.

1045

We thank GB foods for producing the trial-specific micronutrient-fortified bouillon cubes for this study, particularly Félix Sancho, Juan Carlos Velasco, and Patricia Lopez. We thank DSM for preparing the micronutrient premix and Symrise for preparing the specific flavouring used in the trial cubes. Colleagues at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), along with members of a consortium created the model bouillon formulation used in this study and advised on technical issues related to bouillon storage and management.

1052

1053 The Bill & Melinda Gates Foundation Design Analyze Communicate (DAC) team provided helpful comments on an early version of the study protocol and facilitated trial design simulations 1054 1055 by Mediana. We further appreciate the technical and overall guidance of Dipika Matthias (PATH), Ann Tarini (independent consultant), and colleagues at Helen Keller International. We 1056 acknowledge the UCSF MLK Cores Research Facility for support with sample analysis plans. 1057 Finally, we thank Yakubu Adams and Felix Kyereh (University of Ghana) and Dr. Lindsay Allen 1058 1059 (USDA) for contributions to study preparations, Dr. Elizabeth Prado (UC Davis) for guidance on 1060 child development assessments, Lauren Thompson (UC Davis) for assistance with stool collection 1061 protocols, Dr. Michael Green (The Pennsylvania State University), Dr. Anthony Oxley and Dr. Alice Goddard (Newcastle University) for support with RID assessment. 1062

1063	Online Supporting Material	
1064		
1065	S1. Table of primary outcomes	
1066	S2. Table of secondary outcomes	
1067	S3. Table of specification and definitions of hemoglobin and micronutrient biomarker variables	
1068	for children 2-5 years of age	
1069	S4. Table of specification and definitions of hemoglobin and micronutrient biomarker variables	
1070	for non-pregnant, non-lactating women of reproductive age	
1071	S5. Supplemental Methods: Inclusion, Exclusion, and Deferral Criteria	
1072		
1073		
1074		
1075	References	
1076		
1077	1. Stevens GA, Beal T, Mbuya MNN, Luo H, Neufeld LM. Micronutrient deficiencies among	
1078	preschool-aged children and women of reproductive age worldwide: a pooled analysis of	
1079	individual-level data from population-representative surveys. Lancet Glob Health.	
1080	2022;10(11):e1590-e9. Epub 2022/10/15. doi: 10.1016/s2214-109x(22)00367-9. PubMed PMID:	
1081	36240826.	
1082	2. Stevens G, Bennett J, Hennocq Q, Lu Y, De-Regil L, Rogers L, et al. Trends and mortality	
1083	effects of vitamin A deficiency in children in 138 low-income and middle-income countries	
1084	between 1991 and 2013: a pooled analysis of population-based surveys. Lancet Glob Health.	
1085	2015;3:e528-36.	
1086	3. Rogers LM, Cordero AM, Pfeiffer CM, Hausman DB, Tsang BL, De-Regil LM, et al.	
1087	Global folate status in women of reproductive age: a systematic review with emphasis on	

1088 methodological issues. Ann N Y Acad Sci. 2018;1431(1):35-57. Epub 2018/09/22. doi:

1089 10.1111/nyas.13963. PubMed PMID: 30239016; PubMed Central PMCID: PMCPMC6282622.

1090 4. Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies.

- 1091 Ann Nutr Metab. 2015;66 Suppl 2:22-33. Epub 2015/06/06. doi: 10.1159/000371618. PubMed
- 1092 PMID: 26045325.
- 1093 5. Alderman H. The economic cost of a poor start to life. Journal of developmental origins of

1094 health and disease. 2010;1(1):19-25. Epub 2010/02/01. doi: 10.1017/s2040174409990158.

1095 PubMed PMID: 25142929.

1096 6. Global Fortification Data Exchange [16/05/2023]. Available from:

- 1097 <u>http://www.fortificationdata.org</u>.
- 1098 7. Wegmüller R, Bentil H, Wirth JP, Petry N, Tanumihardjo SA, Allen L, et al. Anemia,

1099 micronutrient deficiencies, malaria, hemoglobinopathies and malnutrition in young children and

1100 non-pregnant women in Ghana: Findings from a national survey. PLoS One.

1101 2020;15(1):e0228258. Epub 2020/01/31. doi: 10.1371/journal.pone.0228258. PubMed PMID:

1102 31999737; PubMed Central PMCID: PMCPMC6991996 are responsible for the views expressed in

this publication and they do not necessarily represent the decisions, policy or views of UNICEF.

1104 This does not alter our adherence to PLOS ONE policies on sharing data and materials.'.

1105 8. University of Ghana, GroundWork, University of Wisconsin-Madison, KEMRI-Wellcome

1106 Trust, UNICEF. Ghana Micronutrient Survey 2017. Accra, Ghana: 2017.

1107 9. Nyumuah RO, Hoang TC, Amoaful EF, Agble R, Meyer M, Wirth JP, et al. Implementing

large-scale food fortification in Ghana: lessons learned. Food Nutr Bull. 2012;33(4 Suppl):S293-

- 1109 300. Epub 2013/03/01. doi: 10.1177/15648265120334s305. PubMed PMID: 23444710.
- 1110 10. Univ Ghana/GroundWork/Univ Wisconsin-Madison/KEMRI/UNICEF. Ghana
- 1111 Micronutrient Survey [Internet]. UNICEF-Accra, Accra, Ghana [cited 2019-05-21]. Available

1112 from: http://groundworkhealth.org/wp-content/uploads/2018/06/UoG-GroundWork 2017-

1113 GHANA-MICRONUTRIENT-SURVEY Final 180607.pdf. 2017.

1114 11. Osendarp SJM, Martinez H, Garrett GS, Neufeld LM, De-Regil LM, Vossenaar M, et al.

1115 Large-Scale Food Fortification and Biofortification in Low- and Middle-Income Countries: A

1116 Review of Programs, Trends, Challenges, and Evidence Gaps. Food Nutr Bull. 2018;39(2):315-31.

1117 Epub 2018/05/26. doi: 10.1177/0379572118774229. PubMed PMID: 29793357; PubMed Central

1118 PMCID: PMCPMC7473077.

1119 12. Matthias D, McDonald CM, Archer N, Engle-Stone R. The Role of Multiply-Fortified

1120 Table Salt and Bouillon in Food Systems Transformation. Nutrients. 2022;14(5). Epub 2022/03/11.

1121 doi: 10.3390/nu14050989. PubMed PMID: 35267964; PubMed Central PMCID:

1122 PMCPMC8912775.

1123 13. Garcia-Casal MN, Peña-Rosas JP, McLean M, De-Regil LM, Zamora G. Fortification of

1124 condiments with micronutrients in public health: from proof of concept to scaling up. Ann N Y

1125 Acad Sci. 2016;1379(1):38-47. Epub 2016/08/11. doi: 10.1111/nyas.13185. PubMed PMID:

1126 27508517.

1127 14. Engle-Stone R, Adams KP, Kumordzie SM, Luo H, Wessells K, Adu-Afarwuah S, et al.,

editors. Analyses using national survey data from Cameroon, Haiti, and Ghana indicate the

1129 potential for bouillon fortification to help fill dietary gaps for 5 nutrients2021: Current

1130 Developments in Nutrition.

1131 15. Engle-Stone R, Nankap M, Ndjebayi AO, Brown KH. Simulations based on representative

1132 24-h recall data predict region-specific differences in adequacy of vitamin A intake among

1133 Cameroonian women and young children following large-scale fortification of vegetable oil and

1134 other potential food vehicles. J Nutr. 2014;144(11):1826-34.

1135 16. Hess SY, Brown KH, Sablah M, Engle-Stone R, Aaron GJ, Baker SK. Results of

1136 Fortification Rapid Assessment Tool (FRAT) surveys in sub-Saharan Africa and suggestions for

future modifications of the survey instrument. Food Nutr Bull. 2013;34(1):21-38. Epub

1138 2013/06/19. doi: 10.1177/156482651303400104. PubMed PMID: 23767278.

1139 17. Kumordzie SK, Adams KP, Arnold CD, Tan X, Vosti SA, Engle-Stone R. Assessment of

the potential Impact of bouillon fortification on micronutrient Intakes in Ghana using a household

1141 expenditure survey. Submission to Micronutrient Forum 2020 conference: 2019.

1142 18. Klassen-Wigger P, Geraets M, Messier MC, Detzel P, Lenoble HP, Barclay DV. Chapter

1143 39 - Micronutrient fortification of bouillon cubes in Central and West Africa. Food Fortification in

a Globalized World: Academic Press; 2018. p. 363-72.

1145 19. Spohrer R, Knowles J, Jallier V, Ndiaye B, Indorf C, Guinot P, et al. Estimation of

1146 population iodine intake from iodized salt consumed through bouillon seasoning in Senegal. Ann

1147 N Y Acad Sci. 2015;1357:43-52. Epub 2016/01/16. doi: 10.1111/nyas.12963. PubMed PMID:

1148 26767583.

1149 20. Abizari AR, Dold S, Kupka R, Zimmermann MB. More than two-thirds of dietary iodine in

1150 children in northern Ghana is obtained from bouillon cubes containing iodized salt. Public Health

1151 Nutr. 2017;20(6):1107-13. Epub 2016/12/03. doi: 10.1017/s1368980016003098. PubMed PMID:

1152 27903312.

1153 21. Engle-Stone R, Nankap M, Ndjebayi AO, Brown KH. Simulations based on representative

1154 24-h recall data predict region-specific differences in adequacy of vitamin A intake among

1155 Cameroonian women and young children following large-scale fortification of vegetable oil and

1156 other potential food vehicles. J Nutr. 2014;144(11):1826-34. Epub 2014/10/22. doi:

1157 10.3945/jn.114.195354. PubMed PMID: 25332482.

1158 22. Vosti SA, Kagin J, Engle-Stone R, Luo H, Tarini A, Clermont A, et al. Strategies to

1159 achieve adequate vitamin A intake for young children: Options for Cameroon. Ann N Y Acad Sci.

1160 2020;1465(1):161-80. doi: 10.1111/nyas.14275.

- 1161 23. Luo H, Stewart CP, Brown KH, Engle-Stone R. Predicted effects of current and potential
- 1162 micronutrient intervention programs on adequacy of iron intake in a national sample of women and
- 1163 young children in Cameroon. Micronutrient Forum; Cancun, Mexico2016.
- 1164 24. Green MH, Ford JL, Green JB, Berry P, Boddy AV, Oxley A, et al. A Retinol Isotope
- 1165 Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults
- 1166 Based on Data from an Early Postdosing Blood Sample. J Nutr. 2016;146(10):2137-42. Epub
- 1167 2016/08/12. doi: 10.3945/jn.116.233676. PubMed PMID: 27511937; PubMed Central PMCID:
- 1168 PMCPMC5037874.
- 1169 25. Affairs DoEaS. Designing household survey samples: Practical guidelines. New York:
- 1170 United Nations, 2005 Contract No.: ST/ESA/STAT/SER.F/98.
- 1171 26. Friesen VM, Jungjohann S, Mbuya MNN, Harb J, Visram A, Hug J, et al. Fortification
- 1172Assessment Coverage Toolkit (FACT) Manual. Global Alliance for Improved Nutrition (Geneva)
- and Oxford Policy Management (Oxford), 2019.
- 1174 27. Green MH, Green JB. Use of Model-Based Compartmental Analysis and Theoretical Data
- to Further Explore Choice of Sampling Time for Assessing Vitamin A Status in Groups and
- 1176 Individual Human Subjects by the Retinol Isotope Dilution Method. J Nutr. 2021;151(7):2068-74.
- 1177 Epub 2021/04/10. doi: 10.1093/jn/nxab061. PubMed PMID: 33834213; PubMed Central PMCID:
- 1178 PMCPMC8245873.
- 1179 28. Kumordzie SM, Davis JN, Adams KP, Tan X, Adu-Afarwuah S, Wessells K, et al.
- 1180 Understanding patterns and drivers of bouillon use in Northern Ghana to inform fortification
- 1181 planning. Curr Dev Nutr. 2021;5:655.
- 1182 29. Allen L, de Benoist B, Dary O, Hurrell R, editors. Guidelines on food fortification with
 1183 micronutrients. Geneva: World Health Organization; 2006.
- 1184 30. Hackl L, Cercamondi CI, Zeder C, Wild D, Adelmann H, Zimmermann MB, et al.
- 1185 Cofortification of ferric pyrophosphate and citric acid/trisodium citrate into extruded rice grains

- doubles iron bioavailability through in situ generation of soluble ferric pyrophosphate citrate 1186
- complexes. The American journal of clinical nutrition. 2016;103(5):1252-9. Epub 2016/04/08. doi: 1187
- 1188 10.3945/ajcn.115.128173. PubMed PMID: 27053382.
- 31. Global Alliance for Improved Nutrition (GAIN), Ghana Health Service, UNICEF. National 1189 Iodine Survey Report Ghana 2015. 2017. 1190
- 32. Kumordzie SM, Wessells K, Becher E, Davis JN, Arnold CD, Tan X, et al. Acceptability 1191
- 1192 of multiple micronutrient-fortified bouillon cubes among women in 2 districts int he northern
- region of Ghana. Curr Dev Nutr. 2022;6(Suppl 1):586. 1193
- 1194 33. Food and Nutrition Board (FNB) Institute of Medicine (IOM). Dietary Reference Intakes
- for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, 1195
- Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington D.C.: National Academy Press, 1196 1197 2001.
- Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for 1198 34.
- Measurement of Household Food Access: Indicator Guide (v. 3). Washington, D.C.: FHI 1199
- 1200 360/FANTA, 2007.
- Young SL, Boateng GO, Jamaluddine Z, Miller JD, Frongillo EA, Neilands TB, et al. The 35. 1201
- Household Water InSecurity Experiences (HWISE) Scale: development and validation of a 1202
- household water insecurity measure for low-income and middle-income countries. BMJ Glob 1203
- 1204 Health. 2019;4(5):e001750. Epub 2019/10/23. doi: 10.1136/bmjgh-2019-001750. PubMed PMID:
- 1205 31637027; PubMed Central PMCID: PMCPMC6768340.
- Organization WH. STEPS Instrument version 3.2 [Internet]. STEPwise Approach to NCD 1206 36.
- Risk Factor Surveillance (STEPS) [cited 2022 April 29]. Available from: 1207
- 1208 https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps.

1209 37. Indicators for assessing infant and young child feeding practices: definitions and

- measurement methods. Geneva: World Health Organization and United Nations Children's Fund(UNICEF), 2021.
- 1212 38. Herforth AW, Wiesmann D, Martínez-Steele E, Andrade G, Monteiro CA. Introducing a
- 1213 Suite of Low-Burden Diet Quality Indicators That Reflect Healthy Diet Patterns at Population
- 1214 Level. Curr Dev Nutr. 2020;4(12):nzaa168. Epub 2020/12/22. doi: 10.1093/cdn/nzaa168. PubMed

1215 PMID: 33344879; PubMed Central PMCID: PMCPMC7723758.

- 1216 39. Birch LL, Fisher JO, Grimm-Thomas K, Markey CN, Sawyer R, Johnson SL.
- 1217 Confirmatory factor analysis of the Child Feeding Questionnaire: a measure of parental attitudes,
- beliefs and practices about child feeding and obesity proneness. Appetite. 2001;36(3):201-10.
- 1219 Epub 2001/05/19. doi: 10.1006/appe.2001.0398. PubMed PMID: 11358344.

1220 40. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy of iron

1221 and zinc intakes in developing countries: Washington, DC and Cali, Colombia: International Food

1222 Policy Research Institute (IFPRI) and International Center for Tropical Agriculture (CIAT); 2008.

1223 41. Caswell BL, Arnold CD, Engle-Stone R, Davis JN, Olney DK, Stewart CP. Open Dietary

1224 Recall System (OpenDRS): An open-access, tablet-based 24-hour dietary recall tool. in review.

1225 2023.

1226 42. Cashin K, Oot L. Guide to Anthropometry. A practical tool for program planners,

1227 managers, and implementers. Washington, D.C.: Food and Nutrition Technical Assistance III

- 1228 Project (FANTA)/FHI 360, 2018.
- 1229 43. Gladstone M, Lancaster G, Umar E, Nyirenda M, Kayira E, van den Broek N, et al. The

1230 Malawi Developmental Assessment Tool (MDAT): The creation, validation, and reliability of a

tool to assess child development in rural African settings. PloS Med. 2010;7:e1000273.

1232 44. Howard SJ, Melhuish E. An Early Years Toolbox for Assessing Early Executive Function,

1233 Language, Self-Regulation, and Social Development: Validity, Reliability, and Preliminary

1234 Norms. J Psychoeduc Assess. 2017;35(3):255-75. Epub 2017/05/16. doi:

- 1235 10.1177/0734282916633009. PubMed PMID: 28503022; PubMed Central PMCID:
- 1236 PMCPMC5424850.
- 1237 45. Caldwell BM, Bradley RH. Home observation for measurement of the environment:
- administration manual. Family & Human Dynamics Research Institute, Arizona State University,
- 1239 2003.
- 1240 46. International Zinc Nutrition Consultative Group (IZiNCG). Assessment of the risk of zinc
- 1241 deficiency in populations and options for its control. Hotz C, Brown KH, eds. Food and Nutrition
- 1242 Bulletin. 2004;25 (suppl 2):S91-204.
- 1243 47. Stoltzfus R, Underwood B. Breast-milk vitamin A as an indicator of vitamin A status of
- women and infants. Bull World Health Organ. 1995;73:703-11.
- 1245 48. Lucas A, Gibbs JA, Lyster RL, Baum JD. Creamatocrit: simple clinical technique for
- estimating fat concentration and energy value of human milk. Br Med J. 1978;1(6119):1018-20.
- 1247 Epub 1978/04/22. PubMed PMID: 638579; PubMed Central PMCID: PMCPMC1604026.
- 1248 49. Erhardt JG, Estes JE, Pfeiffer CM, Biesalski HK, Craft NE. Combined measurement of
- 1249 ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an
- 1250 inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. J
- 1251 Nutr. 2004;134(11):3127-32. Epub 2004/10/30. doi: 10.1093/jn/134.11.3127. PubMed PMID:
- 1252 15514286.
- 1253 50. Engle-Stone R, Miller JC, Reario MFD, Arnold CD, Stormer A, Lafuente E, et al. Filipino
- 1254 Children with High Usual Vitamin A Intakes and Exposure to Multiple Sources of Vitamin A
- 1255 Have Elevated Total Body Stores of Vitamin A But Do Not Show Clear Evidence of Vitamin A
- 1256 Toxicity. Curr Dev Nutr. 2022;6(8):nzac115. Epub 2022/09/06. doi: 10.1093/cdn/nzac115.
- 1257 PubMed PMID: 36060221; PubMed Central PMCID: PMCPMC9429969.

- 1258 51. Bieri J, Tolliver T, Catignani G. Simultaneous determination of alpha-tocopherol and
- 1259 retinol in plasma or red cells by high pressure liquid chromatography. The American journal of
- 1260 clinical nutrition. 1979;32(10):2143-9. doi: 10.1093/ajcn/32.10.2143.
- 1261 52. Turner T, Burri BJ, Jamil KM, Jamil M. The effects of daily consumption of beta-
- 1262 cryptoxanthin-rich tangerines and beta-carotene-rich sweet potatoes on vitamin A and carotenoid
- 1263 concentrations in plasma and breast milk of Bangladeshi women with low vitamin A status in a
- 1264 randomized controlled trial. The American journal of clinical nutrition. 2013;98(5):1200-8. Epub
- 1265 2013/09/06. doi: 10.3945/ajcn.113.058180. PubMed PMID: 24004891.
- 1266 53. Killilea DW, Schultz K. Pre-analytical variables influence zinc measurement in blood1267 samples. PLOS ONE. 2023.
- 1268 54. Pfeiffer CM, Zhang M, Lacher DA, Molloy AM, Tamura T, Yetley EA, et al. Comparison
- 1269 of serum and red blood cell folate microbiologic assays for national population surveys. J Nutr.
- 1270 2011;141(7):1402-9. Epub 2011/05/27. doi: 10.3945/jn.111.141515. PubMed PMID: 21613453;
- 1271 PubMed Central PMCID: PMCPMC3113292.
- 1272 55. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, et al.
- 1273 Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. J Nutr.
- 1274 2016;146(9):1816s-48s. Epub 2016/08/12. doi: 10.3945/jn.115.229708. PubMed PMID:
- 1275 27511929; PubMed Central PMCID: PMCPMC4997277.
- 1276 56. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics.1277 2000;56:645-6.
- 1278 57. Bland JM, Altman DG. Best (but oft forgotten) practices: testing for treatment effects in
- 1279 randomized trials by separate analyses of changes from baseline in each group is a misleading
- approach. The American journal of clinical nutrition. 2015;102(5):991-4. Epub 2015/09/12. doi:
- 1281 10.3945/ajcn.115.119768. PubMed PMID: 26354536.

- 1282 58. O'Connor C, Joffe H. Intercoder reliability in qualitative research: Debates and practical
- 1283 guidelines. International Journal of Qualitative Methods. 2020. doi: 10.1177/1609406919899220.
- 1284 59. International Committee of Medical Journal Editors. Recommendations for the Conduct,
- 1285 Reporting, Editing, and Publication of Scholarly Work in Medical Journals 2022 [cited 2022 May
- 1286 16]. Available from: <u>https://www.icmje.org/icmje-recommendations.pdf</u>.
- 1287 60. Engle-Stone R, Vosti SA, Luo H, Kagin J, Tarini A, Adams KP, et al. Weighing the risks
- 1288 of high intakes of selected micronutrients compared with the risks of deficiencies. Ann N Y Acad
- 1289 Sci. 2019;1446(81-101).
- 1290
- 1291
- 1292
- 1293

Online Supporting Material: Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status among women and children in two districts in the Northern Region of Ghana: Protocol for the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized controlled trial.

Physiological group **Primary outcomes** Non-pregnant, non-lactating Change in micronutrient status after 38 weeks: • women of reproductive age Total body vitamin A stores and liver vitamin A concentration 0 (WRA) (measured by retinol isotope dilution) Plasma ferritin and soluble transferrin receptor (sTfR) 0 concentrations, and calculated body iron stores (BIS) Plasma zinc concentration 0 Erythrocyte folate concentrations 0 Plasma vitamin B12 concentration 0 Change in hemoglobin (Hb) concentration after 38 weeks • Children 2-5 y Change in micronutrient status after 38 weeks: • Plasma retinol binding protein (RBP) concentrations 0 Plasma ferritin and soluble transferrin receptor (sTfR) 0 concentrations, and calculated body iron stores (BIS) 0 Plasma zinc concentration Plasma folate concentration 0 0 Plasma vitamin B12 concentration Change in hemoglobin concentration after 38 weeks • Non-pregnant, lactating • Change in breast milk vitamin A concentration after 12 weeks women (controlling for milk fat content) Change in breast milk vitamin B12 concentration after 12 weeks •

S1. Table of primary outcomes

Online Supporting Material: Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status among women and children in two districts in the Northern Region of Ghana: Protocol for the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized controlled trial.

Target group	Secondary outcomes
Household	• Household consumption of bouillon (total and per capita)
	 Adherence (consumption of study-provided bouillon, expressed as % of
	total household bouillon consumption)
Non-pregnant, non-	• Change in serum or plasma retinol and retinol binding protein (RBP)
lactating women of	concentrations after 38 weeks
reproductive age	• Change in serum folate concentrations after 38 weeks
	• Change in urinary iodine concentrations after 38 weeks
	• Urinary sodium concentrations, and sodium:potassium ratio
	• Change in prevalence of micronutrient deficiency after 38 weeks
	• Change in prevalence of anaemia after 38 weeks
	• Inflammation (concentrations of C-reactive protein (CRP) and alpha-1-
	acid glycoprotein (AGP) and prevalence of elevated values, and other
	markers including amyloid A, monocyte chemoattractant protein-1
	(MCP-1), IL-6, IL-10, IL1beta, and adiponectin at baseline and endline
	• Current or recent malaria (by rapid diagnostic test; RDT) at baseline
	and endline
	• Morbidity (cumulative days of symptoms over study duration)
	• Dietary intake of bouillon, salt, fortifiable foods, energy,
	macronutrients, and micronutrients
	Blood pressure and hypertension prevalence
Children 2-5 y	• Change in urinary iodine concentrations after 38 weeks
	• Change in prevalence of micronutrient deficiency after 38 weeks
	Change in prevalence of anaemia after 38 weeks
	• Change in plasma retinol concentrations after 38 weeks
	• Inflammation (concentrations of C-reactive protein (CRP) and alpha-
	a-acid glycoprotein (AGP) and prevalence of elevated values) at
	baseline and endline
	• Current or recent malaria (by RDT) at baseline and endline
	• Faecal calprotectin concentrations at baseline and endline
	• Faecal microbiota at baseline and endline
	• Morbidity (cumulative days of symptoms over study duration)
	• Dietary intake of bouillon, salt, fortifiable foods, energy,
	macronutrients, and micronutrients
	• Anthropometric measurements (change in height-for-age and weight-
	for-height Z-scores; prevalence of stunting and wasting)
	• Change in Malawi Development Assessment Tool (MDAT) scores in
	4 domains (gross motor, fine motor, language, social) after 38 weeks
Non progrant lastating	Change in Early Years Toolbox (EYT) scores after 38 weeks
Non-pregnant, lactating women	• Change in prevalence of low milk nutrient concentrations after 12 weeks
WUIIICII	
	• Dietary intake of bouillon, salt, fortifiable foods, energy,
	 macronutrients, and micronutrients Morbidity (cumulative days of symptoms over study duration)
l	Morbidity (cumulative days of symptoms over study duration)

S2. Table of secondary outcomes

S3. Table of specification and definitions of hemoglobin and micronutrient biomarker variables for children 2-5 years of age¹

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 110 g/L (WHO, 2011)
Mild anemia	Hb 100-109 g/L
Moderate to severe anemia	Hb 70-99 g/L
Severe anemia	Hb < 70 g/L
Plasma ferritin (µg/L)	
Iron deficiency (low plasma ferritin	Plasma ferritin < 12 μ g/L (WHO, 2011)
concentration)	
Plasma soluble transferrin receptor	
concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (Erhardt, Estes, Pfeiffer, Biesalski,
	& Craft, 2004)
Any iron deficiency	Plasma ferritin $\leq 12 \ \mu g/L$ and/or sTfR $\geq 8.3 \ mg/L$
Iron deficiency anemia	(plasma ferritin <12 μ g/L and/or sTfR > 8.3 mg/L) and Hb <
	110 g/L (World Health Organization)
Low ferritin and anemia	Plasma ferritin <12 μ g/L and Hb < 110 g/L (World Health
	Organization)
Body iron stores (BIS; mg/kg)	
Low BIS	< 0 mg/kg (Cook, Flowers, & Skikne, 2003)
Plasma zinc concentration (μ g/dL)	
Low plasma zinc concentration	Plasma zinc $< 65 \ \mu g/dL$ (Brown et al., 2004)
Plasma retinol concentration (µmol/L)	
Low retinol	Plasma retinol < 0.70 µmol/L (WHO, 2011)
Marginal retinol	Plasma retinol < 1.05 µmol/L
Plasma retinol binding protein	
concentration (RBP; μ mol/L) ²	
Low RBP	Study-specific cut-off to be determined
Marginal RBP	Study-specific cut-off to be determined
Plasma folate concentrations (nmol/L)	
Low folate	< 10 nmol/L (L. B. Bailey et al., 2015)
Low folate and anemia	Plasma folate < 10 nmol/L and anemia (Hb < 120 g/L)
Plasma vitamin B12 concentrations	
(pmol/L)	
Low vitamin B12	< 148 pmol/L (Allen et al., 2018)
Depleted vitamin B12	< 221 pmol/L
Low B12 and anemia	Vitamin B12 < 148 pmol/L and anemia (Hb < 120 g/L)

Low B12 and anemiaVitamin B12 < 148 pmol/L and anemia (Hb < 120 g/L)</th>¹Hb, hemoglobin; BIS, body iron stores; RBP, retinol binding protein; sTfR, soluble transferrin receptor.Procedures for adjusting micronutrient biomarkers for inflammation and methodological factors, as
appropriate, will be described in the Statistical Analysis Plan. ²There is currently no internationally
established cut-off for RBP that reflects a plasma retinol concentration of < 0.70 µmol/L or < 1.05
µmol/L, and it has been recommended that trials determine the relationship between retinol and RBP in a
sub-sample of the trial population to establish study-specific RBP cut-offs.

S4. Table of specification and definitions of hemoglobin and micronutrient biomarkers		
variables for non-pregnant, non-lactating women of reproductive age 1		

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 120 g/L (WHO, 2011)
Mild anemia	Hb 110-119 g/L
Moderate to severe anemia	Hb 80-109 g/L
Severe anemia	Hb < 80 g/L
Hematocrit (Hct; L/L)	
Anemia	Hct < 0.36 L/L (World Health Organization)
Plasma ferritin (μ g/L)	
Iron deficiency (low plasma ferritin	Plasma ferritin < 15 μ g/L (WHO, 2011)
concentration)	
Plasma soluble transferrin receptor	
concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (Erhardt et al., 2004)
Any iron deficiency	Plasma ferritin <15 μ g/L and/or sTfR > 8.3 mg/L
Iron deficiency anemia	(Plasma ferritin $<15 \ \mu\text{g/L}$ and/or sTfR $> 8.3 \ \text{mg/L}$) and (Hb
non denerency unenna	< 120 g/L or Het < 0.36 L/L)
Low ferritin and anemia	Plasma ferritin <15 μ g/L and (Hb < 120 g/L or Hct < 0.36
	L/L
Body iron stores (BIS; mg/kg)	
Low BIS	BIS < 0 mg/kg (Cook et al., 2003)
Plasma zinc concentration (µg/dL)	
Low plasma zinc concentration	Plasma zinc $< 70 \ \mu g/dL$ (fasting); $< 66 \ \mu g/dL$ (non-
Low plasma zine concentration	fasting) (Brown et al., 2004)
Liver vitamin A concentrations	
Low liver vitamin A concentrations	< 0.07 µmol/g liver and < 0.1 µmol/g liver
Serum (plasma) retinol concentration	
(μmol/L)	
Low retinol	Serum (plasma) retinol < 0.70 µmol/L (WHO, 2011)
Marginal retinol	Serum (plasma) retinol < $0.76 \ \mu mol/L$
Plasma retinol binding protein	
concentration (RBP; μ mol/L) ²	
Low RBP	Study-specific cut-off to be determined
Marginal RBP	Study-specific cut-off to be determined
Serum folate concentrations (nmol/L)	
Low serum folate	< 10 nmol/L (L. B. Bailey et al., 2015)
Erythrocyte (RBC) folate concentrations	
Low RBC folate	< 340 nmol/L (L. B. Bailey et al., 2015)
Low folate and anemia	RBC folate < 340 nmol/L or serum folate < 10nmol/L and
	anemia (Hb < 120 g/L)
Plasma vitamin B12 concentrations	
(pmol/L)	
Low vitamin B12	< 148 pmol/L (Allen et al., 2018)
Depleted vitamin B12	< 221 pmol/L
Low B12 and anemia	Vitamin B12 < 148 pmol/L and anemia (Hb < 120 g/L)

¹Hb, hemoglobin; Hct, haematocrit; BIS, body iron stores; RBC, red blood cell; RBP, retinol binding protein; sTfR, soluble transferrin receptor. Procedures for adjusting micronutrient biomarkers for inflammation and methodological factors, as appropriate, will be described in the Statistical Analysis Plan. ²There is currently no internationally established cut-off for RBP that reflects a plasma retinol concentration of $< 0.70 \ \mu$ mol/L or $< 1.05 \ \mu$ mol/L, and it has been recommended that trials determine the relationship between retinol and RBP in a sub-sample of the trial population to establish study-specific RBP cut-offs.

S5. Supplemental Methods: Inclusion, Exclusion, and Deferral Criteria

Inclusion/exclusion criteria at recruitment (home visit):

Household

Inclusion criteria are:

(i) Head of household provides oral consent for the participation of household members (index participants), and willingness to have study-provided bouillon cubes used in their household cooking for the next 10 months;

Exclusion criteria are:

- (i) Reported chronic medical condition requiring frequent blood transfusion (e.g. severe forms of thalassemia) among any household members;
- (ii) Current participation of any household member in a clinical trial;
- (iii)Reported shrimp, wheat, milk, soy, eggs, celery, fish, or mollusk allergy, or a previous adverse reaction to bouillon by the participant or any member of their household.

Non-pregnant, non-lactating women of reproductive age (WRA)

Inclusion criteria are:

- (i) Non-pregnant non-lactating women of reproductive age (15 49 years);
- (ii) Signed the informed consent form (or in the case of adolescents 15-17 years of age, unmarried and still living with their parents, assent provided from the index participant and consent from a parent or guardian);
- (iii) Planning to remain in the study area for the next 10 months;
- (iv) Willing to use study-provided bouillon in household cooking for the next 10 months;
- (v) Not planning to become pregnant during the next 10 months.

Potential participants will be excluded if any of the following apply:

- (i) Severe illness warranting immediate hospital referral;
- (ii) COVID-19 diagnosis or exposure¹ in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual

¹ Exposure based on the WHO definition: "A contact is defined as anyone who had direct contact or was within 1 metre for at least 15 minutes with a person infected with the virus that causes COVID-19." <u>https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-contact-tracing</u>. Diagnosis may be based on positive test or diagnosis by a medical professional based on clinical symptoms.

may repeat eligibility assessment once after a deferral period of at least 2 weeks];

- (iv) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status;
- (v) Unable to provide informed consent due to impaired decision-making abilities.

Children 2-5 years of age (24-59 mo)

Inclusion criteria are:

- (i) Child 2-5 years of age (24-59 mo);
- (ii) Signed informed consent for the child's participation from a parent or guardian;
- (iii) Planning to remain in the study area for the next 10 months;
- (iv) Caregiver willing to use study-provided bouillon in household cooking for the next 10 months.

Potential participants will be excluded if any of the following apply:

- (i) Severe illness warranting immediate hospital referral;
- (ii) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iii) Presence of morbidity symptoms suggesting COVID-19 infection (fever, [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iv) Mid-upper arm circumference (MUAC) < 11.5 cm;
- (v) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status.

Lactating women

Inclusion criteria are:

- (i) Non-pregnant women of reproductive age (15 49 years); currently breastfeeding a child who is 4-18 months of age;
- (ii) Signed the informed consent form (or in the case of adolescents 15-17 years of age, unmarried and still living with their parents, provide assent from the index participant and consent from a parent or guardian);
- (iii) Planning to remain in the study area for the next 4 months;
- (iv) Planning to breastfeed for the next 4 months;
- (v) Willing to use study-provided bouillon in household cooking for the next 4 months;
- (vi) Not planning to become pregnant during the next 4 months.

Potential participants will be excluded if any of the following apply:

- (i) Pregnancy (determined by self-report);
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever[temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (v) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status;
- (vi) Unable to provide informed consent due to impaired decision-making abilities.

Exclusion criteria at <u>baseline</u> screening visit (WRA only):

Non-pregnant, non-lactating women of reproductive age

Potential participants will be excluded if any of the following apply:

- (i) Hemoglobin < 80 g/L **at baseline screening visit**;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (v) Recent diarrhea [≥3 liquid or semiliquid stools in 72 hours]) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (vi) Reported consumption of vitamin A-rich foods (e.g., liver) in the previous 24 hours [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (vii) Pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin, HCG, on the day of isotope dosing);
- (viii) Incomplete consumption of vitamin A isotope dose;
- (ix) Positive malaria RDT on the day of isotope dosing [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (x) CRP > 5 mg/L on the day of isotope dosing [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks].

Exclusion criteria at baseline visit:

Non-pregnant, non-lactating women of reproductive age

- (i) Hemoglobin < 80 g/L;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (v) Pregnancy (determined by self-report).

Children 2-5 years of age

- (i) Hemoglobin < 70 g/L;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (v) Severe acute malnutrition at baseline (weight-for-height Z-score < -3 SD or bilateral oedema).

Lactating women

- (i) Severe illness warranting immediate hospital referral;
- (xi) COVID-19 diagnosis or exposure in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (xii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, or loss of taste or smell within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];
- (ii) Pregnancy (determined by self-report);
- (iii) Cessation of lactation, or planning to discontinue breastfeeding in the next three months.

Exclusion criteria during course of the intervention:

Non-pregnant, non-lactating women of reproductive age

- (i) Pregnancy (determined by self-report);
- (ii) Pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin at the endline 1 visit [pre-endline isotope dosing]).

Lactating women

- (i) Cessation of lactation (determined by self-report);
- (ii) Pregnancy (determined by self-report).

Note: If a COVID-19 exposure or diagnosis, or if COVID-19-related morbidity symptoms are reported during biweekly visits during the intervention trial, the participant will be allowed to remain enrolled, but field staff will follow procedures for "no contact" study activities (e.g., "no contact" bouillon ration drop-off) for a 2-week period.

Deferral criteria for endline assessments

Replicate endline assessments (3 weeks apart for blood biomarkers and 1 week apart for breast milk biomarkers) will be conducted for each of the primary outcomes except estimation of total body vitamin A stores among women. For all participants, each endline assessment will be deferred if any of the following apply:

- (i) COVID-19 exposure or positive test in the previous two weeks [individual may repeat eligibility assessment once after a deferral period of at least 3 weeks for WRA and children or at least 2 weeks for lactating women];
- (ii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature ≥ 38°C], chills/shaking, dry cough, shortness of breath or difficulty breathing, or loss of taste or smell within the past 72 hours) [individual may repeat eligibility assessment once after a deferral period of at least 3 weeks for WRA and children or at least 2 weeks for lactating women].

For a participant who has both endline visits deferred, the maximum duration of participation in the study would be 44 weeks (that is, if Endline 1 is deferred from 35 weeks to 38 weeks and Endline 2 is deferred from 41 weeks to 44 weeks). In this case the household would continue to receive their usual supply of study bouillon cubes until the participants complete the Endline 2 visit. Based on pilot data we expect this situation to be rare.

Note: If a non-pregnant, non-lactating WRA has a hemoglobin concentration < 80 g/L, or a 2-5 year old child has a hemoglobin concentration < 70 g/L or a WHZ < -3 SD at the first endline

visit, participants may remain in the trial, but will not participate in the second endline blood sample.

Additional exclusion criteria for pre-endline isotope dose (WRA only):

Non-pregnant, non-lactating women of reproductive age

The pre-endline vitamin A isotope dose will be administered after the endline 1 blood sample. The isotope dose will not be given if any of the following apply:

(i) Hemoglobin < 80 g/L

Additional deferral criteria for pre-endline isotope dose (WRA only):

Non-pregnant, non-lactating women of reproductive age

The pre-endline vitamin A isotope dose will be administered after the endline 1 blood sample. The isotope dose will be deferred if any of the following apply:

- (i) Recent diarrhea [≥3 liquid or semiliquid stools in 72 hours]) [individual may repeat eligibility assessment once after a deferral period of at least 3 weeks];
- (ii) Reported consumption of vitamin A-rich foods (e.g., liver) in the previous 24 hours [individual may repeat eligibility assessment up once after a deferral period of at least 3 weeks];
- (iii) Positive malaria RDT on the day of isotope dosing [individual may repeat eligibility assessment once after a deferral period of at least 3 weeks];
- (iv) CRP > 5 mg/L on the day of isotope dosing [individual may repeat eligibility assessment once after a deferral period of at least 3 weeks].